Category: Covid 19

  • MIL-OSI New Zealand: Backing for food banks extended

    Source: NZ Music Month takes to the streets

    The Government will back community-based food banks for a further year as New Zealand recovers from a cost-of-living crisis, Minister for Social Development and Employment Louise Upston says.
    “The $15 million in support announced today will be managed by the Ministry of Social Development (MSD), the New Zealand Food Network and partner agencies – meaning help for people who continue to need it.
    “This will support the work of the Food Network, regional food hubs and community food providers, as they jointly distribute more than 4.5 million meals a month.
    “Existing funding for the Food Secure Communities Programme was a Covid response measure and never intended to be permanent. It would have expired at the end of June 2024, but we know demand remains high, mainly driven by the cost of living.
    “That’s why continuing support for food security remains important, with the Treasury expecting the pace of economic recovery to be slower than previously forecast.
    “Our $15 million investment in the community food sector for 2025/26 will support and maintain: 

    national and regional food distribution infrastructure to distribute purchased and rescued bulk food to community providers at low or no cost and during emergencies and disruptive events ($7.9 million)
    food security initiatives which increase community food resilience and self-sufficiency ($1 million)
    food providers and hubs to purchase and/or distribute food through foodbanks and community centres to meet the increased demand for food support ($6 million)

    “This investment in food security also complements other Government initiatives supporting families and children, such as FamilyBoost. It also aligns with Government targets to increase student attendance and achievement. Addressing food insecurity also contributes to wider priorities on health, employment, and tackling violence and crime.
    “Because it’s also important for the Government to know whether social investment and community initiatives are working, this funding includes $100,000 for MSD to better understand the programme’s impact while wider decisions are made about the future of food security programmes,” Louise Upston says.
     

    MIL OSI New Zealand News

  • MIL-OSI Security: City of Miami Police Officer Pleads Guilty to COVID-19 Relief Fraud

    Source: Office of United States Attorneys

    MIAMI – Yesterday, Tramaine Liptrot, 43, a police officer with the City of Miami Police Department (MPD) who has been relieved of duty, pleaded guilty to wire fraud in connection with fraudulent applications for two Paycheck Protection Program (PPP) loans totaling over $200,000. Liptrot entered his guilty plea in Miami before U.S. District Judge Beth Bloom.

    According to the facts admitted at the change of plea hearing, Liptrot, along with being an MPD Police Officer, was the owner and President of Liptrots Tax Services L.L.C (Liptrots Tax). With the assistance of an associate, Liptrot fraudulently obtained two PPP loans in the name of Liptrots Tax.

    On June 22, 2020, working with the associate, Liptrot caused the submission of a false and fraudulent PPP loan application on behalf of Liptrots Tax, falsely claiming that Liptrots Tax had an average monthly payroll of $36,700 for four employees, and a fraudulent IRS Form 944 in support thereof, falsely claiming that Liptrots Tax paid its employees $440,397 during 2019. As a result of this fraudulent PPP application, Liptrots Tax obtained approximately $91,750 in PPP loan proceeds from an SBA approved PPP lender.

    On March 3, 2021, again working with the associate, Liptrot caused the submission of a false and fraudulent second-draw PPP loan application on behalf of Liptrots Tax, falsely claiming that Liptrots Tax had an average monthly payroll of $43,369, and including as part of the application process, a fraudulent IRS Form 944, falsely claiming that Liptrots Tax paid $496,428 in wages and other compensation in 2020. As a result of this fraudulent second-draw PPP application, Liptrots Tax obtained approximately $108,422 in PPP loan proceeds from a different SBA approved PPP lender. 

    Liptrot is scheduled for sentencing on August 6, 2025, at 10:30 a.m., where he faces a possible maximum sentence of up to 20 years in prison.

    U.S. Attorney Hayden P. O’Byrne for the Southern District of Florida, acting Special Agent in Charge Brett D. Skiles of FBI Miami and Special Agent in Charge Amaleka McCall-Brathwaite, U.S. Small Business Administration Office of Inspector General (SBA-OIG), Eastern Region, announced the guilty plea.

    FBI Miami’s Area Corruption Task Force, which includes task force officers from the City of Miami Police Department’s Internal Affairs Section, and SBA-OIG investigated the case. Assistant U.S. Attorney Edward N. Stamm is prosecuting the case and Assistant U.S. Attorney Gabrielle Raemy Charest-Turken is handling asset forfeiture.

    In March 2020, the Coronavirus Aid, Relief, and Economic Security (CARES) Act was enacted. It was designed to provide emergency financial assistance to the millions of Americans suffering the economic effects caused by the COVID-19 pandemic. Among other sources of relief, the CARES Act authorized and provided funding to the SBA to provide Economic Injury Disaster Loans (EIDLs) to eligible small businesses, including sole proprietorships and independent contractors, experiencing substantial financial disruptions due to the COVID-19 pandemic to allow them to meet financial obligations and operating expenses that could otherwise have been met had the disaster not occurred.  EIDL applications were submitted directly to the SBA via the SBA’s on-line application website, and the applications were processed and the loans funded for qualifying applicants directly by the SBA.

    On May 17, 2021, the Attorney General established the COVID-19 Fraud Enforcement Task Force to marshal the resources of the Department of Justice in partnership with agencies across government to enhance efforts to combat and prevent pandemic-related fraud. The Task Force bolsters efforts to investigate and prosecute the most culpable domestic and international criminal actors and assists agencies tasked with administering relief programs to prevent fraud by, among other methods, augmenting and incorporating existing coordination mechanisms, identifying resources and techniques to uncover fraudulent actors and their schemes, and sharing and harnessing information and insights gained from prior enforcement efforts. For more information on the Department’s response to the pandemic, please visit https://www.justice.gov/coronavirus.

    On September 15, 2022, the Attorney General selected the Southern District of Florida’s U.S. Attorney’s Office to head one of three national COVID-19 Fraud Strike Force Teams. The Department of Justice established the Strike Force to enhance existing efforts to combat and prevent COVID-19 related financial fraud. For more information on the department’s response to the pandemic, please click here.

    Anyone with information about allegations of attempted fraud involving COVID-19 can report it by calling the Department of Justice’s National Center for Disaster Fraud (NCDF) Hotline at 866-720-5721 or via the NCDF Web Complaint Form at: https://www.justice.gov/disaster-fraud/ncdf-disaster-complaint-form.

    Related court documents and information may be found on the website of the District Court for the Southern District of Florida at www.flsd.uscourts.gov or at http://pacer.flsd.uscourts.gov, under case number 23-cr-20155.

    ###

    MIL Security OSI

  • MIL-OSI: Solar Alliance announces major stride towards profitability and files audited financial results

    Source: GlobeNewswire (MIL-OSI)

    TORONTO and KNOXVILLE, Tenn., May 21, 2025 (GLOBE NEWSWIRE) — Solar Alliance Energy Inc. (‘Solar Alliance’ or the ‘Company’) (TSX-V: SOLR, OTC: SAENF), a leading solar energy solutions provider focused on the commercial and utility solar sectors, has filed its audited financial results for the quarter and year ended December 31, 2024 (the “Financial Statements”) and related Management’s Discussion and Analysis (“MD&A”). The Financial Statements and related MD&A are available under the Company’s profile.at  www.sedarplus.ca

    While Revenues in 2024 fell, from the record level of 2023, gross profits improved, and losses fell substantially as the Company approached breakeven.

    “Solar Alliance continues to see strong interest in renewable energy and strong demand for commercial solar projects. In recent years, the Company has honed its skill and laid down a track record in delivering C&I (commercial and industrial) and smaller utility projects. In the course of 2024, Solar Alliance completed 3MW from multiple smaller 100kW to 500kW projects. The Company has now moved toward a business development strategy targeting larger commercial projects in the 1MW to 5MW range, which the board believes we can deliver profitably, to support robust future growth. In recent years, overhead was decreased as we pursued a more focussed strategy. We now have the platform in place to target larger projects and we will selectively add resources to build on that and exploit the opportunities we have identified,”. said Solar Alliance CEO, Brian Timmons.

    We are well down the path to build a stable, growing company that is well positioned to take advantage of the broader shift to renewable energy. In this context, we closely monitor developments as they relate to the energy industry. We are encouraged to see an appreciation that the availability of competitively priced energy is a key factor underpinning future US economic growth. In the face of burgeoning energy demand over the next two decades the key market drivers that affect our business remain in place.

    Key financial highlights for 2024

    • Revenue decreased year-over-year to $5,446,757 (2023, $7,473,937) for the year ended December 31, 2024, as the Company focused on completion of a number of projects begun in 2023.
    • Cost of sales of $3,873,917 (2023, $6,399,169) resulting in a gross profit of $1,572,840 (2023, $1,074,768).
    • Net cash used in operating activities $1,830,685 (2023 – Net cash used by operating activities, $51,500)
    • Net Cash provided (absorbed) by financing activities $845,000 (2023 – ($127,500))
    • Net loss of $684,134 (2023 loss $1,811,861).
    • Total expenses of $2,869,308 (2023 – $3,037,881), reduction of 5.5%.
    • Salaries and benefits of $1,367,439 (2023 – $1,343,363), a 2% increase.
    • Short-term loans and notes payable of $227,621 in 2024 (2023 – $137,500).

    Key business highlights and outlook

    Large project focus momentum. The Company continues to benefit from repeat customers while focusing on new customers’ opportunities for solar system sales and installations. Recent policy developments in our area of operations, and growing interest in community solar is increasing the number of opportunities in our target market.

    Small and medium-sized project growth continues. This remains a target niche as a base flow of business. An important component for small and rural businesses wanting to reduce utility costs are the Rural Energy for America Program (“REAP”) grants and loans disbursed by the United States Department of Agriculture (“USDA”).  This market segment would be impinged upon by changes in the USDA REAP scheme, although recently the administration did provide guidance enabling our customers’ grant applications to move forward. These projects are in addition to the sales funnel of larger projects the Company continues to pursue.

    Regional focus and Building on our expertise. Solar Alliance’s strategy is to design, engineer and install, operate and manage, and in due course, participate in ownership of commercial solar systems ranging in size from one to five megawatts. Demonstrated success in the region and improved processes create opportunities for further sales and development opportunities.

    Restatement of Comparative Period as at December 31, 2023

    The Company announces that certain items in the financial statements for the year ended December 31, 2023 have been restated to correct certain classification errors in such financial statements. Please refer to Note 22 of the audited financial statements for the year ended December 31, 2024 for a fulsome description of adjustments and restatements for the year ended December 31, 2023.

    Brian Timmons, CEO

    About Solar Alliance Energy Inc. (www.solaralliance.com)

    Solar Alliance is an energy solutions provider focused on the commercial, utility and community solar sectors. Our experienced team of solar professionals reduces or eliminates customers’ vulnerability to rising energy costs, offers an environmentally friendly source of electricity generation, and provides affordable, turnkey clean energy solutions. Solar Alliance’s strategy is to ultimately build, own and operate our own solar assets while also generating stable revenue through the sale and installation of solar projects to commercial and utility community customers.

    Statements in this news release, other than purely historical information, including statements relating to the Company’s future plans and objectives or expected results, constitute Forward-looking statements.

    The words “would”, “will”, “expected” and “estimated” or other similar words and phrases are intended to identify forward-looking information. Forward-looking information in this news release includes, but is not limited to, statements with respect to the Company’s business development strategy, that the Company will be targeting larger commercial projects and the belief that the Company may deliver larger commercial projects profitably. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, level of activity, performance or achievements to be materially different than those expressed or implied by such forward-looking information. Such factors include but are not limited to: the ability to complete the Company’s projects on schedule or at all, uncertainties related to the ability to raise sufficient capital; changes in economic conditions or financial markets; litigation, legislative or other judicial, regulatory, legislative and political competitive developments; technological or operational difficulties; the ability to maintain revenue growth; the ability to execute on the Company’s strategies; the ability to complete the Company’s current and backlog of solar projects; the ability to grow the Company’s market share; the high growth rate of the US solar industry; the ability to convert the backlog of projects into revenue; the expected timing of the construction and completion of the 1500 kW Kentucky solar projects; the targeting of larger customers; the ability to predict and counteract the effects, should they re-emerge, of COVID-19 on the business of the Company, including but not limited to the effects of COVID-19, on the construction sector, capital market conditions, restriction on labour and international travel and supply chains; potential corporate growth opportunities and the ability to execute on the key objectives in 2025. Consequently, actual results may vary materially from those described in the forward-looking statements.

    “Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.”

    The MIL Network

  • MIL-OSI Global: FDA limits access to COVID-19 vaccine to older adults and other high-risk groups – a public health expert explains the new rules

    Source: The Conversation – USA – By Libby Richards, Professor of Nursing, Purdue University

    Older adults will continue to receive yearly COVID-19 shots, but lower-risk groups will not, says the FDA. dusanpetkovic via iStock / Getty Images Plus

    On May 20, 2025, the Food and Drug Administration announced a new stance on who should receive the COVID-19 vaccine.

    The agency said it would approve new versions of the vaccine only for adults 65 years of age and older as well as for people with one or more risk factors for severe COVID-19 outcomes. These risk factors include medical conditions such as asthma, cancer, chronic kidney disease, heart disease and diabetes.

    However, healthy younger adults and children who fall outside of these groups may not be eligible to receive the COVID-19 shot this fall. Vaccine manufacturers will have to conduct clinical trials to demonstrate that the vaccine benefits low-risk groups.

    FDA Commissioner Martin Makary and the agency’s head of vaccines, Vinay Prasad, described the new framework in an article published in the New England Journal of Medicine and in a public webcast.

    The Conversation U.S. asked Libby Richards, a nursing professor involved in public health promotion, to explain why the changes were made and what they mean for the general public.

    Why did the FDA diverge from past practice?

    Until the May 20 announcement, getting a yearly COVID-19 vaccine was recommended for everyone ages 6 months and older, regardless of their health risk.

    According to Makary and Prasad, the Food and Drug Administration is moving away from these universal recommendations and instead taking a risk-based approach based on its interpretation of public health trends – specifically, the declining COVID-19 booster uptake, a lack of strong evidence that repeated boosters improve health outcomes for healthy people and the fact that natural immunity from past COVID-19 infections is widespread.

    The FDA states it wants to ensure the vaccine is backed by solid clinical trial data, especially for low-risk groups.

    Was this a controversial decision or a clear consensus?

    The FDA’s decision to adopt a risk-based framework for the COVID-19 vaccine aligns with the expected recommendations from the Advisory Committee on Immunization Practices, an advisory group of vaccine experts offering expert guidance to the Centers for Disease Control and Prevention on vaccine policy, which is scheduled to meet in June 2025. But while this advisory committee was also expected to recommend allowing low-risk people to get annual COVID-19 vaccines if they want to, the FDA’s policy will likely make that difficult.

    Although the FDA states that its new policy aims to promote greater transparency and evidenced-based decision-making, the change is controversial – in part because it circumvents the usual process for evaluating vaccine recommendations. The FDA is enacting this policy change by limiting its approval of the vaccine to high-risk groups, and it is doing so without any new data supporting its decision. Usually, however, the FDA broadly approves a vaccine based on whether it is safe and effective, and decisions on who should be eligible to receive it are left to the CDC, which receives research-based guidance from the Advisory Committee on Immunization Practices.

    Change is coming to COVID-19 vaccine policy.
    Rock Obst, CC BY-SA

    Additionally, FDA officials point to Canada, Australia and some European countries that limit vaccine recommendations to older adults and other high-risk people as a model for its revised framework. But vaccine strategies vary widely, and this more conservative approach has not necessarily proven superior. Also, those countries have universal health care systems and have a track record of more equitable access to COVID-19 care and better COVID-19 outcomes.

    Another question is how health officials’ positions on COVID-19 vaccines affect public perception. Makary and Prasad noted that COVID-19 vaccination campaigns may have actually eroded public trust in vaccination. But some vaccine experts have expressed concerns that limiting COVID-19 vaccine access might further fuel vaccine hesitancy because any barrier to vaccine access can reduce uptake and hinder efforts to achieve widespread immunity.

    What conditions count as risk factors?

    The New England Journal of Medicine article includes a lengthy list of conditions that increase the risk of severe COVID-19 and notes that about 100 million to 200 million people will fall into this category and will thus be eligible to get the vaccine.

    Pregnancy is included. Some items on the list, however, are unclear. For example, the list includes asthma, but the data that asthma is a risk factor for severe COVID-19 is scant.

    Also on the list is physical inactivity, which likely applies to a vast swath of Americans and is difficult to define. Studies have found links between regular physical activity and reduced risk of severe COVID-19 infection, but it’s unclear how health care providers will define and measure physical inactivity when assessing a patient’s eligibility for COVID-19 vaccines.

    Most importantly, the list leaves out an important group – caregivers and household members of people at high risk of severe illness from COVID-19 infection. This omission leaves high-risk people more vulnerable to exposure to COVID-19 from healthy people they regularly interact with. Multiple countries the new framework refers to do include this group.

    Why is the FDA requiring new clinical trials?

    According to the FDA, the benefits of multiple doses of COVID-19 vaccines for healthy adults are currently unproven. It’s true that studies beyond the fourth vaccine dose are scarce. However, multiple studies have demonstrated that the vaccine is effective at preventing the risk of severe COVID-19 infection, hospitalization and death in low-risk adults and children. Receiving multiple doses of COVID-19 vaccines has also been shown to reduce the risk of long COVID.

    The FDA is moving to risk-based access for COVID-19 vaccines.

    The FDA is requiring vaccine manufactures to conduct additional large randomized clinical trials to further evaluate the safety and effectiveness of COVID-19 boosters for healthy adults and children. These trials will primarily test whether the vaccines prevent symptomatic infections, and secondarily whether they prevent hospitalization and death. Such trials are more complex, costly and time-consuming than the more common approach of testing for immunological response.

    This requirement will likely delay both the timeliness and the availability of COVID-19 vaccine boosters and slow public health decision-making.

    Will low-risk people be able to get a COVID-19 shot?

    Not automatically. Under the new FDA framework, healthy adults who wish to receive the fall COVID-19 vaccine will face obstacles. Health care providers can administer vaccines “off-label”, but insurance coverage is widely based on FDA recommendations. The new, narrower FDA approval will likely reduce both access to COVID-19 vaccines for the general public and insurance coverage for COVID-19 vaccines.

    The FDA’s focus on individual risks and benefits may overlook broader public health benefits. Communities with higher vaccination rates have fewer opportunities to spread the virus.

    What about vaccines for children?

    High-risk children age 6 months and older who have conditions that increase the risk of severe COVID-19 are still eligible for the vaccine under the new framework. As of now, healthy children age 6 months and older without underlying medical conditions will not have routine access to COVID-19 vaccines until further clinical trial data is available.

    Existing vaccines already on the market will remain available, but it is unclear how long they will stay authorized and how the change will affect childhood vaccination overall.

    Libby Richards has received funding from the National Institutes of Health, the American Nurses Foundation, and the Indiana Clinical and Translational Sciences Institute

    ref. FDA limits access to COVID-19 vaccine to older adults and other high-risk groups – a public health expert explains the new rules – https://theconversation.com/fda-limits-access-to-covid-19-vaccine-to-older-adults-and-other-high-risk-groups-a-public-health-expert-explains-the-new-rules-257226

    MIL OSI – Global Reports

  • MIL-OSI Global: Universal vaccines could reshape how we fight future outbreaks – but a broad approach is needed

    Source: The Conversation – UK – By Antony Black, Lecturer, Life Sciences, University of Westminster

    raker/Shutterstock.com

    Every year, the race begins anew. Scientists scramble to track mutating viruses, pharmaceutical companies reformulate vaccines and public health systems brace for another season of jabs and logistics.

    This relentless cycle is our frontline defence against threats like flu and COVID – but it comes at a steep price. Globally, billions are poured into strain and variant surveillance, vaccine development and distribution, leaving already-stretched health systems — particularly in lower-income countries – struggling to keep pace.

    That’s why scientists have long aimed to develop universal vaccines – ones that protect against all major forms of a virus, including both seasonal and pandemic types. But designing these vaccines has proved to be tricky.

    The difficulty lies in the way viruses mutate. Influenza and SARS-CoV-2 (the virus that causes COVID) change rapidly, allowing them to escape the immune system’s memory responses triggered by past infections or vaccinations. To make a universal vaccine, researchers must identify parts of the virus that stay the same across different strains and variants – known as “conserved regions”.


    Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK’s latest coverage of news and research, from politics and business to the arts and sciences.


    These conserved regions are harder for the immune system to recognise, so scientists are developing strategies to enhance the body’s response to them. One approach removes the rapidly mutating parts of the virus from the vaccine entirely, helping the immune system focus on the parts that don’t change.

    Another strategy involves “mosaic” vaccines, which combine elements from many virus strains to trigger a broad, protective immune response.

    Several technologies used to deliver these vaccines are at various stages of development. For example, mRNA vaccines use lab-made strands of messenger RNA (a type of genetic material) to instruct cells to produce viral proteins to trigger an immune response.

    Another type relies on “viral vectors” – harmless viruses that deliver genetic material into human cells to stimulate immunity. Both types of vaccines were gamechangers during the COVID pandemic.

    Other technologies include nanoparticles, which use synthetic biological particles to improve delivery and immune response. And “virus-like particles”, which trigger immune responses by imitating the structure of viruses, but don’t contain any genetic material.

    Researchers are also using powerful computational tools to design vaccines that could work across multiple strains.

    These platforms aren’t just being explored for flu and COVID – similar efforts are underway for other fast-evolving viruses, such as HIV.

    Cash injection

    Earlier this month, the US government announced a US$500 million (£377 million) investment to accelerate research into universal vaccines. After years of underfunding, experts say this backing is long overdue – especially following the COVID pandemic, which temporarily shifted focus to emergency vaccine production.

    The rapid development of COVID vaccines showed how targeted funding and global collaboration can lead to scientific breakthroughs. A similar approach could now help bring universal vaccines closer to reality by supporting early research, funding clinical trials and improving manufacturing and distribution systems.

    However, the investment has not been without controversy. Some scientists have raised concerns that the funding may be overly directed toward a narrow set of researchers or outdated methods, rather than being open to the most promising technologies.

    Critics argue that a broad, flexible portfolio of vaccine strategies – rather than a single approach – is the key to success.

    Ultimately, the goal of a universal vaccine is not just scientific. It’s also practical and global: reducing the burden on health systems, lowering costs and transforming how the world responds to future outbreaks.

    Antony Black does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

    ref. Universal vaccines could reshape how we fight future outbreaks – but a broad approach is needed – https://theconversation.com/universal-vaccines-could-reshape-how-we-fight-future-outbreaks-but-a-broad-approach-is-needed-256656

    MIL OSI – Global Reports

  • MIL-OSI United Kingdom: Consultation launched on proposed changes to transport for post-16 SEND students

    Source: City of Wolverhampton

    Fees for post-16 SEND travel were due to be introduced in 2020 following consultation but halted due to the outbreak of the Covid pandemic.

    Fresh consultation is now being held on the introduction of a charging policy which will require a contribution towards the cost of post-16 SEND travel.

    This would bring the council in line with the approach taken by neighbouring authorities.

    The proposed charges would apply to students moving into post-16 SEND education from September 2025 and those already in post-16 SEND education.

    Any payments would be spread over 3 terms with a reduction for low income families.

    Councillor Qaiser Azeem, the City of Wolverhampton Council’s Cabinet Member for Transport, said: “We are one of the few remaining councils to offer free transport for this age group. Most authorities charge a contribution due to there being no legal requirement to provide post 16 transport.

    “We remain committed to ensuring young people lead independent healthy lives, feel safe and secure and achieve their full potential.

    “While in an ideal world we would not need to consider introducing charges, the proposals to introduce a contribution towards the cost of post-16 SEND travel, align with, or are less than, neighbouring authorities.

    “We would of course work closely with families affected to support them should these changes be introduced.

    “It is important we hear from parents, carers, students, schools and the wider community as part of this consultation, so please take this opportunity to have your say.”

    In line with legislation there is no transport charge for pupils aged 5 to 16 or for adult learners aged 19 to 25.

    The consultation is now live and runs until 13 June. Take part at Consultation on Post 16 SEND Transport Charges – City of Wolverhampton Council – Citizen Space.
     

    MIL OSI United Kingdom

  • MIL-OSI United Kingdom: ‘Shine your light’: responding to challenges facing the charity sector

    Source: United Kingdom – Executive Government & Departments

    Speech

    ‘Shine your light’: responding to challenges facing the charity sector

    Charity Commission Chief Executive David Holdsworth delivers keynote speech at Charity Times’ Annual Conference 2025.

    Thank you Srabani and good morning everyone / bore da pawb.

    It’s a privilege to be speaking to at this conference for the first time as the Commission’s CEO, after rejoining the organisation last summer.

    I probably don’t need to explain to this audience why I returned to work with the charity sector.

    Current operating environment and challenges 

    The Charity Commission stands at a unique vantage point, where the perspectives of charities, government, the public and donors meet.

    From this position, we see three trends.

    First, an incredibly challenging economic environment for the sector.

    Like other sectors, charities face inflationary pressures and rising operational costs.

    But charities are also dealing with increased demands for their services.

    The cumulative impact of these trends on charities is, in some cases, extremely challenging.

    Second, charities, like other organisations, are contending with rapid technological and social change.

    Some tech innovations, notably in the space of AI, offer tools that can help charities do more with less and increase their impact.

    But looking ahead, these technologies potentially challenge the very role of organisations and institutions in the traditional sense.

    Notably when coupled with changing attitudes, especially among younger people, whose allegiances are increasingly to causes, not ‘bricks and mortar’ or brands and institutions and where technology platforms offer alternatives of direct giving to those in need.  

    Thirdly – global conflicts, geo political shifts and instability. The shocking invasion of Ukraine and conflicts in the middle east have seen demands on and need of charity increase significantly. Whilst at the same time the once seemingly immovable, solid post war geo political system is shifting, creating uncertainty and instability. This makes responding to increased global need more difficult and challenging to navigate.

    Impact and Potential

    Despite those challenges the sector has never been more important – and let’s be clear what charities achieve for society is astonishing, both in terms of scale and impact.

    Based on Annual Returns submitted to the Commission for 2023’s accounts, the sector had an annual income of over £96 billion – up around 7% on the previous year.

    We registered just over 5,000 new charities last year, having assessed a record 9,840 applications – a 9% increase on the previous year.

    And there are around 700,000 trustees who collectively steward the sector though good times and bad, and whose work often goes unrecognised and uncelebrated – though we at the Commission are all too aware of their service and contribution.

    But numbers alone don’t tell of the human impact of charity. Of the positive difference charities make in transforming or enriching communities, our environment, our wildlife, heritage, culture as well as saving and improving countless individual lives.

    It is that impact that charities, their amazing trustees, volunteers and employees have – that we must not lose sight of – nor let the challenges shroud.

    There are so many examples to tell.

    Like the Felix Project which had a landmark year, providing 38 million meals through its network of 1,264 community organisations and schools by growing its network of collaborations. Building on that success it has launched its Multibank, which has seen 1.46 million non-food essential items distributed to try and ensure no Londoner in need goes without.

    Welsh Women’s Aid and its partners helped 739 survivors access refuge-based support. That is life-saving intervention happening every day, across the country – offering not just physical shelter but a sense of home and safety when people need it most.

    That the osprey – that magnificent bird of prey – which was once driven to near extinction in the UK – is now thriving, with over 250 nesting pairs living in Britain today, is thanks to charities.

    And it is thanks to charity that, on average, two lives are saved at sea every single day by RNLI volunteers.  

    Also I know from my last CEO role at the Animal and Plant Health Agency, thanks to animal welfare charities’ campaigning work over decades, the UK now has one of the most advanced legal frameworks protecting animal health and welfare.

    These a just a few examples of what has been made possible by the charity sector.

    Potential and Opportunity

    So whilst I don’t underestimate for one moment the challenges charities face – and which I have seen first hand on my many visits – I would urge you not to let those challenges dim nor shroud the huge impact you are having, everyday.

    I also firmly believe that as Albert Einstein once said:

    in the middle of difficulty lies opportunity.

    Arguably, the bigger the challenge, the greater the opportunity. Ideas previously rejected as too radical; innovation that once felt too big; conversations which felt too challenging can suddenly feel possible – and necessary.

    Take for example, the city I call home, Liverpool. Which is incidentally also the Commission’s main home, where most of our staff are based.

    I grew up in Liverpool in the 1980s. It was a time when the city felt like it had lost its way, with ever increasing challenges and ever dwindling opportunity and resources.

    Today my home city is transformed. And that transformation happened through collaboration – a combination of philanthropic investments, national and local government investment, alongside renewed community action notably in the arts, culture and tourism which acted as catalysts for wider renewal.

    Each individual project mattered, but what made for game-changing transformation was the cumulative impact of collaborative and complementary efforts from a number of actors. And that is true across the sector today.

    Take for example, Fareshare. Working collaboratively, supporting other charities in their network, they’ve helped distribute 92% more food over the last year, and made their budgets go 78% further.

    This resulted in them distributing a whopping 135 million meals, reaching nearly 1 million people.

    If you’ll allow me to return once more to my hometown.

    In late 2024, Zoe’s Place, a hospice in Liverpool which provides care to children, faced an uncertain future. The community of Liverpool, supported by business leaders and politicians, as well as a fellow charity the Institute of our Lady of Mercy, fellow hospice Claire’s Place and regional media collectively rallied to save Zoe’s Place, with the Commission playing a key facilitating role.

    Now, ownership has been transferred to the newly registered Liverpool Zoe’s Place. The charity’s trustees have also finalised plans to build the charity’s new home, securing the continuation of the former charity’s legacy.

    The hospice had been helping families through the unimaginable since 1995 – to see that vital service disappear would have been gutting for the community, and a huge blow to the families who rely on the organisation’s support.

    Instead, by reawakening their community’s passion and pride in the service, the charity will now continue to provide that support for years to come.

    In addition to this kind of public appeal, forging new corporate partnerships is another option being explored by many charities. Indeed, the Charities Aid Foundation estimates that UK businesses contribute around £4 billion to the sector.

    Take one example – a mere stone’s throw from here: national homelessness charity, Shelter.

    The organisation has partnered with clothing brand, Lucy and Yak. Last year they held a successful pop-up shop in Kings Cross, and now, they’ve launched donation boxes in several Lucy and Yak shops across the country encouraging customers to donate clothing.

    Shelter has responded to competition facing charity shops with the rise of preloved selling platforms in an agile and innovative way. Through this partnership, they’ve added a funding stream to their ‘bow’ and potentially reached new supporters.

    But I appreciate that public appeals and new corporate partnerships won’t work for everyone.  

    As a result of the Covid pandemic, many charities needed to re-evaluate their financial resilience and ability to weather further storms – many had dipped into their reserves, while others had little to fall back on.

    With the same desire to ensure services do not come to an end, some charities with similar goals turned to mergers – combining resources to create something more sustainable.

    For example, Community Integrated Care, one of the largest social care providers in the UK, merged with Inspire, a social care provider based in Scotland, in 2023. The charities saw how funding shortfalls, economic pressures and workforce shortages were impacting social care more broadly and chose to secure their future together rather than struggle through apart. And it paid off.

    Community Integrated Care’s income increased by £22 million in the year after the merger, and the charities reported publicly that the merger was a good strategic fit. These charities found strength in unity while continuing to provide that sense of belonging their beneficiaries depend on.

    Mergers are not the answer for all – and I don’t underestimate the work that can be involved in navigating a successful transition. But where you decide a merger is the best way forward, the Commission is on hand.

    Conclusion: strength in collaboration

    I’ve touched upon a few examples today to evidence my underlying confidence in this sector’s collective power. Just as no home is built by a single pair of hands, no lasting social change comes from isolated efforts.

    Our dear late Queen, Elizabeth II, once said:

    On our own, we cannot end wars or wipe out injustice, but the cumulative impact of thousands of small acts of goodness can be bigger than we imagine.

    In the year of the 80th anniversary of Victory in Europe and Victory in Japan we should remember those words and that out of darkness can come something brighter and better than before.

    From the darkness of tyranny, fascism and unfathomable loss came a renewed determination for peace, democracy and equality. That which charities had long fought for then came forward in the form of the NHS, welfare state, expansion of access to higher education, and workers’ rights.

    While the challenges facing society may be less existential, I believe this sector can again play a transformational role across communities, across government, local and national, with businesses and philanthropists to once again tackle our biggest issues with joint purpose.

    There is no greater charity sector in the world than here and my message is clear.

    Keep shining a light, charities.

    Shine a light on your charitable purpose.

    Shine a light of hope, and of refuge to those in need.

    Shine a light on your innovation and impact.

    And always remember that you not only stand on the shoulders of giants, but you too are now building that better brighter future for the next generation.

    Thank you. I look forward to hearing your thoughts, and taking your questions.

    Updates to this page

    Published 21 May 2025

    MIL OSI United Kingdom

  • MIL-OSI United Kingdom: ‘Shine a light’: responding to challenges facing the charity sector

    Source: United Kingdom – Government Statements

    Speech

    ‘Shine a light’: responding to challenges facing the charity sector

    Charity Commission Chief Executive David Holdsworth delivers keynote speech at Charity Times’ Annual Conference 2025.

    Thank you Srabani and good morning everyone / bore da pawb.

    It’s a privilege to be speaking to at this conference for the first time as the Commission’s CEO, after rejoining the organisation last summer.

    I probably don’t need to explain to this audience why I returned to work with the charity sector.

    Current operating environment and challenges 

    The Charity Commission stands at a unique vantage point, where the perspectives of charities, government, the public and donors meet.

    From this position, we see three trends.

    First, an incredibly challenging economic environment for the sector.

    Like other sectors, charities face inflationary pressures and rising operational costs.

    But charities are also dealing with increased demands for their services.

    The cumulative impact of these trends on charities is, in some cases, extremely challenging.

    Second, charities, like other organisations, are contending with rapid technological and social change.

    Some tech innovations, notably in the space of AI, offer tools that can help charities do more with less and increase their impact.

    But looking ahead, these technologies potentially challenge the very role of organisations and institutions in the traditional sense.

    Notably when coupled with changing attitudes, especially among younger people, whose allegiances are increasingly to causes, not ‘bricks and mortar’ or brands and institutions and where technology platforms offer alternatives of direct giving to those in need.  

    Thirdly – global conflicts, geo political shifts and instability. The shocking invasion of Ukraine and conflicts in the middle east have seen demands on and need of charity increase significantly. Whilst at the same time the once seemingly immovable, solid post war geo political system is shifting, creating uncertainty and instability. This makes responding to increased global need more difficult and challenging to navigate.

    Impact and Potential

    Despite those challenges the sector has never been more important – and let’s be clear what charities achieve for society is astonishing, both in terms of scale and impact.

    Based on Annual Returns submitted to the Commission for 2023’s accounts, the sector had an annual income of over £96 billion – up around 7% on the previous year.

    We registered just over 5,000 new charities last year, having assessed a record 9,840 applications – a 9% increase on the previous year.

    And there are around 700,000 trustees who collectively steward the sector though good times and bad, and whose work often goes unrecognised and uncelebrated – though we at the Commission are all too aware of their service and contribution.

    But numbers alone don’t tell of the human impact of charity. Of the positive difference charities make in transforming or enriching communities, our environment, our wildlife, heritage, culture as well as saving and improving countless individual lives.

    It is that impact that charities, their amazing trustees, volunteers and employees have – that we must not lose sight of – nor let the challenges shroud.

    There are so many examples to tell.

    Like the Felix Project which had a landmark year, providing 38 million meals through its network of 1,264 community organisations and schools by growing its network of collaborations. Building on that success it has launched its Multibank, which has seen 1.46 million non-food essential items distributed to try and ensure no Londoner in need goes without.

    Welsh Women’s Aid and its partners helped 739 survivors access refuge-based support. That is life-saving intervention happening every day, across the country – offering not just physical shelter but a sense of home and safety when people need it most.

    That the osprey – that magnificent bird of prey – which was once driven to near extinction in the UK – is now thriving, with over 250 nesting pairs living in Britain today, is thanks to charities.

    And it is thanks to charity that, on average, two lives are saved at sea every single day by RNLI volunteers.  

    Also I know from my last CEO role at the Animal and Plant Health Agency, thanks to animal welfare charities’ campaigning work over decades, the UK now has one of the most advanced legal frameworks protecting animal health and welfare.

    These a just a few examples of what has been made possible by the charity sector.

    Potential and Opportunity

    So whilst I don’t underestimate for one moment the challenges charities face – and which I have seen first hand on my many visits – I would urge you not to let those challenges dim nor shroud the huge impact you are having, everyday.

    I also firmly believe that as Albert Einstein once said:

    in the middle of difficulty lies opportunity.

    Arguably, the bigger the challenge, the greater the opportunity. Ideas previously rejected as too radical; innovation that once felt too big; conversations which felt too challenging can suddenly feel possible – and necessary.

    Take for example, the city I call home, Liverpool. Which is incidentally also the Commission’s main home, where most of our staff are based.

    I grew up in Liverpool in the 1980s. It was a time when the city felt like it had lost its way, with ever increasing challenges and ever dwindling opportunity and resources.

    Today my home city is transformed. And that transformation happened through collaboration – a combination of philanthropic investments, national and local government investment, alongside renewed community action notably in the arts, culture and tourism which acted as catalysts for wider renewal.

    Each individual project mattered, but what made for game-changing transformation was the cumulative impact of collaborative and complementary efforts from a number of actors. And that is true across the sector today.

    Take for example, Fareshare. Working collaboratively, supporting other charities in their network, they’ve helped distribute 92% more food over the last year, and made their budgets go 78% further.

    This resulted in them distributing a whopping 135 million meals, reaching nearly 1 million people.

    If you’ll allow me to return once more to my hometown.

    In late 2024, Zoe’s Place, a hospice in Liverpool which provides care to children, faced an uncertain future. The community of Liverpool, supported by business leaders and politicians, as well as a fellow charity the Institute of our Lady of Mercy, fellow hospice Claire’s Place and regional media collectively rallied to save Zoe’s Place, with the Commission playing a key facilitating role.

    Now, ownership has been transferred to the newly registered Liverpool Zoe’s Place. The charity’s trustees have also finalised plans to build the charity’s new home, securing the continuation of the former charity’s legacy.

    The hospice had been helping families through the unimaginable since 1995 – to see that vital service disappear would have been gutting for the community, and a huge blow to the families who rely on the organisation’s support.

    Instead, by reawakening their community’s passion and pride in the service, the charity will now continue to provide that support for years to come.

    In addition to this kind of public appeal, forging new corporate partnerships is another option being explored by many charities. Indeed, the Charities Aid Foundation estimates that UK businesses contribute around £4 billion to the sector.

    Take one example – a mere stone’s throw from here: national homelessness charity, Shelter.

    The organisation has partnered with clothing brand, Lucy and Yak. Last year they held a successful pop-up shop in Kings Cross, and now, they’ve launched donation boxes in several Lucy and Yak shops across the country encouraging customers to donate clothing.

    Shelter has responded to competition facing charity shops with the rise of preloved selling platforms in an agile and innovative way. Through this partnership, they’ve added a funding stream to their ‘bow’ and potentially reached new supporters.

    But I appreciate that public appeals and new corporate partnerships won’t work for everyone.  

    As a result of the Covid pandemic, many charities needed to re-evaluate their financial resilience and ability to weather further storms – many had dipped into their reserves, while others had little to fall back on.

    With the same desire to ensure services do not come to an end, some charities with similar goals turned to mergers – combining resources to create something more sustainable.

    For example, Community Integrated Care, one of the largest social care providers in the UK, merged with Inspire, a social care provider based in Scotland, in 2023. The charities saw how funding shortfalls, economic pressures and workforce shortages were impacting social care more broadly and chose to secure their future together rather than struggle through apart. And it paid off.

    Community Integrated Care’s income increased by £22 million in the year after the merger, and the charities reported publicly that the merger was a good strategic fit. These charities found strength in unity while continuing to provide that sense of belonging their beneficiaries depend on.

    Mergers are not the answer for all – and I don’t underestimate the work that can be involved in navigating a successful transition. But where you decide a merger is the best way forward, the Commission is on hand.

    Conclusion: strength in collaboration

    I’ve touched upon a few examples today to evidence my underlying confidence in this sector’s collective power. Just as no home is built by a single pair of hands, no lasting social change comes from isolated efforts.

    Our dear late Queen, Elizabeth II, once said:

    On our own, we cannot end wars or wipe out injustice, but the cumulative impact of thousands of small acts of goodness can be bigger than we imagine.

    In the year of the 80th anniversary of Victory in Europe and Victory in Japan we should remember those words and that out of darkness can come something brighter and better than before.

    From the darkness of tyranny, fascism and unfathomable loss came a renewed determination for peace, democracy and equality. That which charities had long fought for then came forward in the form of the NHS, welfare state, expansion of access to higher education, and workers’ rights.

    While the challenges facing society may be less existential, I believe this sector can again play a transformational role across communities, across government, local and national, with businesses and philanthropists to once again tackle our biggest issues with joint purpose.

    There is no greater charity sector in the world than here and my message is clear.

    Keep shining a light, charities.

    Shine a light on your charitable purpose.

    Shine a light of hope, and of refuge to those in need.

    Shine a light on your innovation and impact.

    And always remember that you not only stand on the shoulders of giants, but you too are now building that better brighter future for the next generation.

    Thank you. I look forward to hearing your thoughts, and taking your questions.

    Updates to this page

    Published 21 May 2025

    MIL OSI United Kingdom

  • WHO members adopt global pandemic accord, but US absence casts doubts

    Source: Government of India

    Source: Government of India (4)

    Members of the World Health Organization adopted an agreement on Tuesday intended to improve preparedness for future pandemics following the disjointed global response to COVID-19, but the absence of the U.S. cast doubt on the treaty’s effectiveness.

    After three years of negotiations, the legally binding pact was adopted by the World Health Assembly in Geneva. WHO member countries welcomed its passing with applause.

    The pact was touted as a victory for members of the global health agency at a time when multilateral organisations like the WHO have been battered by sharp cuts in U.S. foreign funding.

    “The agreement is a victory for public health, science and multilateral action. It will ensure we, collectively, can better protect the world from future pandemic threats,” said WHO Director-General Tedros Adhanom Ghebreyesus.

    The pact aims to ensure that drugs, therapeutics and vaccines are globally accessible when the next pandemic hits. It requires participating manufacturers to allocate a target of 20% of their vaccines, medicines and tests to the WHO during a pandemic to ensure poorer countries have access.

    However, U.S. negotiators left discussions about the accord after President Donald Trump began a 12-month process of withdrawing the U.S. – by far the WHO’s largest financial backer – from the agency when he took office in January.

    Given this, the U.S., which poured billions of dollars into vaccine development during the COVID pandemic, would not be bound by the pact. And WHO member states would not face penalties if they failed to implement it.

    U.S. Health and Human Services Secretary Robert F. Kennedy Jr. slammed the World Health Organization in a video address to the Assembly, saying it had failed to learn from the lessons of the pandemic with the new agreement.

    “It has doubled down with the pandemic agreement which will lock in all of the dysfunction of the WHO pandemic response… We’re not going to participate in that,” he said.

    LATE CHALLENGE

    The deal was reached after Slovakia called for a vote on Monday, as its COVID-19 vaccinesceptic prime minister demanded that his country challenge the adoption of the agreement.

    One hundred and twenty-four countries voted in favour, no countries voted against, while 11 countries, including Poland, Israel, Italy, Russia, Slovakia and Iran, abstained.

    Some health experts welcomed the treaty as a step towards greater fairness in global health after poorer nations were left short of vaccines and diagnostics during the COVID-19 pandemic.

    “It contains critical provisions, especially in research and development, that — if implemented — could shift the global pandemic response toward greater equity,” Michelle Childs, Policy Advocacy Director at Drugs for Neglected Diseases initiative, told Reuters.

    Others said the agreement did not meet initial ambitions and that, without strong implementation frameworks, it risked falling short in a future pandemic.

    “It is an empty shell… It’s difficult to say that it’s a treaty with firm obligation where there is a strong commitment… It’s a good starting point. But it will have to be developed,” said Gian Luca Burci, an academic adviser at the Global Health Centre at the Geneva Graduate Institute, an independent research and education organisation.

    Helen Clark the co-Chair of The Independent Panel for Pandemic Preparedness and Response, described the accord as a foundation to build from.

    “Many gaps remain in finance, equitable access to medical countermeasures and in understanding evolving risks,” she added.

    The pact will not go into effect until an annex on sharing of pathogenic information is agreed. Negotiations on this would start in July with the aim of delivering the annex to the World Health Assembly for adoption, WHO said. A Western diplomatic source suggested it may take up to two years to be agreed.

    (Reuters)

  • MIL-OSI Security: Business Owner Pleads Guilty to Fraud and Money Laundering Schemes

    Source: United States Department of Justice (National Center for Disaster Fraud)

    PHILADELPHIA – United States Attorney David Metcalf announced that Zaven Yeghiazaryan, 44, of Newtown, Pennsylvania, pleaded guilty before the Honorable Gerald J. Pappert to 13 counts of an indictment charging him with conspiracy, health care fraud, wire fraud, and money laundering in connection with his execution of a variety of schemes.

    The charges arose from the defendant’s commission of fraud offenses targeting, among others, government programs, including through the use of shell companies and false identities, between January 2020 and April 2024. The defendant’s fraud offenses targeted two government programs which offered relief during the Covid-19 pandemic: the Small Business Administration’s Economic Injury Disaster Loan program, and the Pandemic Unemployment Assistance Program. In addition, the defendant admitted that he participated in a scheme to defraud the Medicaid program.

    Based upon his guilty pleas to the 13 counts, the defendant faces a maximum possible sentence of 230 years in prison, a three-year period of supervised release, and a $3,250,000 fine, restitution of $334,905 and forfeiture. Sentencing is scheduled for September 4, 2025.

    The case was investigated by the Social Security Administration – Office of the Inspector General, Internal Revenue Service – Criminal Investigation, the United States Postal Inspection Service, Homeland Security Investigations, the Department of Health and Human Services – Office of Inspector General, the United States Department of Labor, the United States Department of Transportation – Office of the Inspector General and the State Department. It is being prosecuted by Assistant United States Attorneys Mary E. Crawley and Special Assistant United States Attorney Megan Curran. 

    MIL Security OSI

  • MIL-OSI China: China urges US to stop politicizing COVID-19 origins tracing

    Source: People’s Republic of China – State Council News

    A spokesperson for the Chinese Mission to the United Nations Office at Geneva on Tuesday urged the United States to end its politicization of COVID-19 origins tracing and stop exerting pressure on international organizations.

    In response to the groundless remarks made by the U.S. delegation at the ongoing 78th World Health Assembly (WHA), the spokesperson said it is astonishing that the United States — a country that once announced its withdrawal from the World Health Organization (WHO) — is now baselessly attacking countries that have consistently stepped up support for the organization. The United States has evidently lost its basic sense of right and wrong. China has always offered selfless support, instead of so-called undue influence, to the WHO, the spokesperson said in a statement.

    The spokesperson stressed that since the outbreak of COVID-19, China has shared information and the genetic sequence of the virus with the international community at the earliest possible time. It has also provided medical supplies and financial assistance to the WHO and 153 countries, including the United States. This reflects China’s commitment to safeguarding the common good of all humanity.

    China supports scientific origins tracing led by the WHO and has invited WHO expert teams to China multiple times for joint studies. These efforts resulted in the authoritative scientific conclusion that a lab leak of COVID-19 from China is “extremely unlikely,” demonstrating China’s openness and transparency on the issue, the spokesperson said.

    The spokesperson pointed out that certain countries, in an attempt to cover up their own poor pandemic response, have resorted to smearing others. Such political manipulation of pandemic issues is disgraceful and doomed to fail. The United States still owes the international community a convincing explanation for the concerns raised by various parties about the origins and handling of the pandemic on its own territory.

    China urges the United States to share its early case data with the WHO and be transparent about Fort Detrick and its network of overseas biological laboratories. The United States should stop political manipulation over COVID-19 origins tracing and cease pressuring international organizations, the spokesperson stated. 

    MIL OSI China News

  • MIL-OSI Russia: China urges US to stop politicizing COVID-19 source tracing issue

    Translation. Region: Russian Federal

    Source: People’s Republic of China in Russian – People’s Republic of China in Russian –

    Source: People’s Republic of China – State Council News

    GENEVA, May 20 (Xinhua) — A spokesperson for the Chinese Permanent Mission to the United Nations in Geneva on Tuesday called on the United States to stop political manipulation over the issue of tracing the source of COVID-19 and stop pressuring international organizations.

    As the official representative said in response to the baseless statements of the US delegation at the ongoing 78th session of the World Health Assembly, it is astonishing that the United States, a country that once announced its withdrawal from the World Health Organization (WHO), is now making baseless attacks on countries that have consistently increased their contribution to the organization. According to the diplomat, the US has clearly lost its basic understanding of truth and lies. China has always provided selfless support to the WHO, without any so-called undue influence, he emphasized.

    The official representative recalled that since the outbreak of COVID-19, China has shared with the international community information on the epidemiological situation and the genomic sequence of the virus in the shortest possible time. In addition, the Chinese side has provided medical supplies and financial assistance to the WHO and 153 countries, including the United States. All this, as the diplomat emphasized, demonstrates China’s firm commitment to protecting the common well-being of all mankind.

    He noted that in an effort to carefully conceal their ineffective anti-epidemic measures, some countries resort to denigrating others. In his opinion, such attempts to politicize pandemic issues are disgusting and doomed to failure.

    China is calling on the United States to share data on early cases with the WHO and to disclose information about the Fort Detrick facility and the network of U.S. biological laboratories around the world, an official said. The U.S. side should stop political manipulation around the issue of tracing the source of COVID-19 and stop pressuring international organizations, he concluded. –0–

    MIL OSI Russia News

  • MIL-OSI United Kingdom: UK adopts historic Pandemic Agreement

    Source: United Kingdom – Government Statements

    Press release

    UK adopts historic Pandemic Agreement

    Better protections for British public and NHS thanks to deal adopted at the World Health Assembly in Geneva.

    • New Agreement will protect British public and NHS from future global health threats while preserving UK sovereignty
    • Pandemic Agreement will safeguard lives and UK economy by improving world’s collective ability to prevent, prepare for, detect and respond to global disease threats
    • This follows long negotiation process to ensure agreement is firmly in UK’s national interest

    The British people, our NHS and the economy will be better protected against future global health threats thanks to a new World Health Organization (WHO) Pandemic Agreement adopted by the UK today.

    The deal marks a significant step forward in stronger domestic and global prevention by improving the way countries around the world work together to detect and combat pandemic threats.

    The UK government has been actively engaged in negotiations to ensure a strong final agreement. The Agreement adopted at the World Health Assembly in Geneva respects national sovereignty while encouraging nations to work together more effectively to address shared global health threats, in turn helping strengthen our national security which is a key part of this government’s Plan for Change. There are no provisions that would give the WHO powers to impose domestic public health decisions on the UK.

    Minister of State for International Development Baroness Chapman said:

    The Pandemic Agreement is a great example of the UK working with our partners to support countries combat disease and strengthen their health systems. Acting together will help us to prevent pandemics, and prepare for and respond to any future pandemic threats.

    Diseases cross borders, and our diplomacy must too, if we are to prevent a repeat of the devastation caused by Covid-19. That’s why this agreement will make the world a healthier and safer place.

    Health Minister Ashley Dalton said:

    COVID-19 showed us the vital importance of international cooperation to save lives. This landmark agreement will help protect British people from future pandemic threats and safeguard our health system, supporting our mission to build an NHS fit for the future.

    Our national interest and the safety and wellbeing of the British public will always be our first priority. This agreement maintains our sovereignty while ensuring the NHS and the UK as a whole will be better prepared for possible future global health emergencies, through stronger early warning systems and faster response capabilities.

    Our world-class life sciences sector will also benefit from increased innovation in vaccines and treatments, boosting growth and improving care for patients across the UK.

    UKHSA Chief Executive Dame Jenny Harries said:

    It is gratifying to see the Pandemic Agreement adopted. It is clear that international co-operation and collaboration must be at the very heart of our pandemic preparedness strategy if it is to be effective, and this agreement is a welcome step towards making the world a safer place from pandemic threats.

    UKHSA has consistently been committed to sharing data and analysis on pathogens with pandemic potential with our international partners, and we will continue to do so as we work to develop the global capacity to respond to emerging threats to public health.

    This is also good news for scientific innovation and the UK’s world-leading life sciences industry, opening the door to enabling high quality vaccines to be delivered faster in the next pandemic.

    The Covid-19 pandemic has had an enduring impact on lives and livelihoods around the world. Thousands of families in the UK lost loved ones, children missed out on pivotal learning and development opportunities, and businesses were forced to close their doors. The estimated cost of the UK government’s COVID-19 measures was over £300 billion.

    The new Pandemic Agreement will help avoid a repeat of this devastation by creating a framework for countries to take action together to better prevent pandemics – by improving disease surveillance so we can detect and respond to new health threats sooner, and by speeding up innovation of life-saving vaccines and treatments.

    The aim is to prevent pandemic threats from emerging in the first place and stopping them in their tracks when they do.

    It will facilitate swifter pathogen and pathogen data sharing so we can act quickly to prevent further spread. It will also enable the UK to develop vaccines, treatments and tests faster, which will help save lives and drive economic growth in our world-leading life sciences sector.

    124 member states agreed to adopt the Pandemic Agreement today, demonstrating strong international commitment to multilateralism and collective action to strengthen global health security.

    The final text represents a strong outcome for the UK. Key wins include: 

    • Commitments on pandemic prevention, including for health, animal, and environmental sectors to collaborate through a “One Health” approach – a major step toward preventing disease spillover from animals to humans;
    • Provisions that will foster innovation, enhance global research and development, and strengthen supply chains;
    • The Pandemic Agreement paves the way for a new and voluntary Pathogen Access and Benefit Sharing (PABS) system which should see pharmaceutical companies get faster access to the pathogens and genetic sequences that they need to create new vaccines, treatments and tests to respond to a pandemic. In return, manufacturers who voluntarily sign up to the system – not the government – will share a portion of their production with the WHO to allocate where it is most needed;
    • The PABS system is entirely voluntary for pharmaceutical companies, who may choose to join to gain faster access to pathogen data for innovation. There are no requirements placed on governments to share vaccines or treatments they have purchased.
    • The Pandemic Agreement does not include any provisions that would give the WHO powers to impose domestic public health decisions on the UK. The sovereignty of states is one of the guiding principles of the Agreement.

    Updates to this page

    Published 20 May 2025

    MIL OSI United Kingdom

  • MIL-OSI United Kingdom: £1 billion BioNTech investment sets way for jobs, growth, breakthroughs

    Source: United Kingdom – Executive Government & Departments 2

    Press release

    £1 billion BioNTech investment sets way for jobs, growth, breakthroughs

    Covid-19 vaccine pioneers BioNTech commit to up to £1 billion, 10-year investment in the UK.

    • Covid-19 vaccine pioneers BioNTech commit to up to £1 billion, 10-year investment in the UK.
    • New research and AI centres to be established in London as well as Cambridge – demonstrating the benefits of the Oxford-Cambridge Growth Corridor – to develop the next generation of life-changing medicines.
    • Underpinned by up to £129 million of government support, this agreement underscores the government’s commitment to life sciences as a key part of the Plan for Change, driving improvements in healthcare, and delivering economic growth.

    Hundreds of highly skilled jobs will be created, and new research centres will be set up aimed at making new advances in medical science, thanks to a planned investment of up to £1 billion into the UK by world-leading biopharmaceutical company BioNTech announced today (Tuesday 20 May).

    This is one of the biggest investments in the history of UK life sciences, made possible with government backing – all part of plans to support this growth-driving sector as part of the Plan for Change, and our mission to turbo-charge economic growth in every part of the country.

    This historic investment is a testament to the confidence in the UK life sciences – one of the priority sectors of the economy that will form a key part of the forthcoming Industrial Strategy – as a driver of economic growth, job creation, and innovations that could overhaul what’s possible in healthcare. The sector is already thriving, worth £108 billion to the economy and providing more than 300,000 highly skilled jobs across the country. But through measures like our commitment to investing up to £520 million in the sector through the Life Sciences Innovative Manufacturing Fund, we want to boost UK life sciences to even greater heights, bolstering our ambitions to grow the economy, create jobs, and building on the UK’s position as the second-most attractive destination for international investment.

    BioNTech will invest in the UK over the course of the next 10 years as part of an ambitious plan to significantly expand their presence here. That will see them create two new R&D hubs, the first to be based in Cambridge, as well as an AI hub to be based at BioNTech’s planned UK headquarters in London. These are planned to create more than 400 new highly skilled jobs over the next 10 years, including researchers in clinical and scientific drug development, bioinformatics, and a range of supporting functions. Indirectly, the investment is also likely to create a substantial number of additional jobs in the supply chain.

    BioNTech are the pioneering company behind mRNA vaccines and cancer immunotherapies notably used to tackle COVID-19, and more recently trialled to help patients with cancer.

    According to the Academy of Medical Sciences, every £1 spent on medical research delivers a return of 25p, every year, forever after that, so the long-term economic impact of an investment in research on this scale, speaks for itself. This is the government’s Plan for Change, in action, and shows how our ambitions for the Oxford-Cambridge Growth Corridor are already pulling international investment into the UK.

    BioNTech signed an agreement finalising the investment together with Science Secretary Peter Kyle today. As part of the agreement, the government will contribute up to £129 million in grant funding over a period of 10 years.

    Science and Technology Secretary Peter Kyle said:

    This investment will propel the growth-driving life sciences sector to new heights, delivering cutting-edge facilities, building careers in the future-facing jobs we want our children to have, and ultimately unlocking progress in medical science that could save lives.

    This is a clear indication of how we will deliver the government’s Plan for Change: working together with the best and brightest businesses and innovators to unlock their potential, and then reap the benefits for the economy, health and more that their drive and genius can deliver.

    Chancellor of the Exchequer, Rachel Reeves, said:

    This is another testament to confidence in Britain being one of the world’s top investment destinations and a global hub for life sciences. It will create hundreds of high-skilled, well-paid jobs, as we deliver on our promise to put more money in working people’s pockets through our Plan for Change.

    CEO and co-founder of BioNTech, Uğur Şahin, said:

    This agreement marks the next chapter of our successful strategic partnership with the UK government. Together, we have already made a meaningful difference in expanding access to investigational personalized cancer therapies for patients. Now, we are taking the next step to accelerate and broaden our research and development efforts advancing towards our vision to translate science into survival for patients.

    In Cambridge, BioNTech plans to set up a new R&D centre focused on genomics, oncology, structural biology, and regenerative medicine. In London, BioNTech intends to establish its UK headquarters, which will be home to a new AI hub led by InstaDeep Ltd, a wholly owned subsidiary of BioNTech SE, and a leading global technology company in the field of AI and machine learning. This hub will enable medical research, using AI, including looking into understanding disease causes, drug target selection and predictive analytics.

    Over time, this work could lead to the discovery and development of new therapies, diagnostics and treatments for a range of diseases that currently cause heartbreak for countless patients and their families – all supporting the mission to rebuild the NHS for the long-term, that sits at the heart of the government’s Plan for Change.

    It also builds on the government’s existing strategic partnership with BioNTech, to provide up to 10,000 patients with investigational personalised cancer immunotherapies by 2030. This is already transforming the experience of patients by broadening access to cancer vaccine trials in the UK.

    The government’s support for BioNTech’s investment is a further example of how we are backing the UK’s thriving life sciences sector to even greater success – following on from the announcement of the Life Sciences Innovative Manufacturing Fund at the Autumn Budget, and strategic collaborations agreed with other innovative life sciences companies. We will say more about our vision for a thriving future for UK life sciences in the forthcoming Life Sciences Sector Plan.

    Steve Bates, CEO of the UK BioIndustry Association, said:

    BioNTech’s investment demonstrates the UK’s position as a top destination for life sciences innovation and underlines why the government is absolutely right to back our sector as a priority for growth.

    BioNTech is not only a pioneer in mRNA science, but also a visionary partner in building a truly unique public-private collaboration with the UK government and NHS – one that sets a benchmark for the world.

    The UK has a once-in-a-lifetime opportunity to leverage its strong position to attract investment from global investors to create well-paid jobs and scale UK companies, if the upcoming Life Sciences Sector Plan can address long-standing structural challenges in the financing and commercial environment.

    Richard Torbett, Chief Executive of the ABPI, said:

    This investment is a testament to the fantastic skills, research capabilities, and scientific infrastructure we have in the UK. It is also a template for how the UK could unlock further life science sector growth by removing the barriers and roadblocks to investment.

    Big investments like this are years in the making and require both sides to have confidence that the other will deliver on their commitments. Trust is slow to build, but this deal shows it is worth the time and the risk.

    Life science companies are already the largest investors in UK R&D – but much of this comes from a handful of companies with deep UK roots. The UK has an opportunity to capture more of the global science pie if we can improve our competitive offering to the sector.

    DSIT media enquiries

    Email press@dsit.gov.uk

    Monday to Friday, 8:30am to 6pm 020 7215 3000

    Updates to this page

    Published 20 May 2025

    MIL OSI United Kingdom

  • MIL-OSI United Kingdom: expert reaction to World Health Assembly adopting WHO Pandemic Agreement

    Source: United Kingdom – Science Media Centre

    Scientists comment on the World Health Assembly adopting the World Health Organisation’s (WHO) Pandemic Agreement.

    Prof Sir Andrew Pollard, Director of the Oxford Vaccine Group; and Ashall Professor of Infection and Immunity at the Pandemic Sciences Institute, University of Oxford, said:

    The pandemic agreement is an important endorsement of a globally collegiate approach to tackling the existential threat we face from a future pandemic.  It recognises the particular challenges highlighted by the COVID19 pandemic around equity in access to life saving vaccines and drugs, the geographical boundaries caused by limited global manufacturing capability and nationalism.  The agreement also highlights the importance of international research coordination so that we are better prepared for the next one.  It shows a level of cooperation and coordination that could make the world a safer place, but the real test of such a document is in its execution.  It is heavily dependent on the actions of the world’s major powers today to lay the groundwork in surveillance, strengthening of health systems distributed manufacturing and research, all of which are severely hampered by the current political and economic headwinds.  We will also critically need such cooperation to remain strong in the face of the next life-threatening microbial invasion of national borders, which will challenge even the most resolute political minds.”

     

    Prof Mishal Khan, Professor of Global Public Health, London School of Hygiene & Tropical Medicine, said:

    “It’s been a huge challenge to get to this point so the fact that this has now been formally agreed at the World Health Assembly, is very welcome.

    “But in reality we won’t know how useful this agreement is until the next pandemic hits.

    “A key question is around whether countries will voluntarily comply with the terms and, if not, how enforceable is it.  Past experience, for example with the International Health Regulations, suggests that powers to enforce will be limited.

    “The success of this treaty will also depend on each country’s capacity to contribute to potentially valuable elements such as the Pathogen Access and Benefit-Sharing System through collecting and sharing high-quality data.

    “It’s concerning that the US will not be bound to the treaty and has not been part of the final discussions, leaving us unsure what its approach to resource and data sharing will be in future disease outbreaks.

    “We must continue to strengthen and support capacity globally to ensure the agreement is equitable and has the best chance of being effective in protecting the world from pandemics.”

     

    Prof Alice Norton, Associate Professor, Pandemic Sciences Institute, University of Oxford, said:

    “The adoption of the Pandemic Agreement by the 78th World Health Assembly today is welcome news for global health security.

    “Article 9 on research and development was one of the first to be unanimously agreed by member state negotiators.  This recognises the ability for science to get us out of a pandemic, as was the case for COVID-19, showing that unlike many other natural disasters we can mitigate the risks and impacts of pandemics through science.

    “Respect for human rights, equity, solidarity and science-based evidence are all key principles rightly enshrined in the Agreement.

    “What will be needed now is the political will and sustainable financing so that all countries can make the Agreement a reality.

    “It is a mistake to believe that our recent experience of a pandemic means we are safe for a while.  The threat of epidemic and pandemic diseases that could devastate lives, livelihoods and economies still loom large.

    “Recent global health funding cuts only serve to worsen our preparedness and response capabilities.  After today’s announcement, governments must now step-up and put the Agreement’s principles into practice.”

    Prof Martin Antonio, Professor of Molecular Microbiology and Global Health based at the MRC Unit The Gambia at LSHTM, and Co-Director of the LSHTM Centre for Epidemic Preparedness and Response, said:

    “Having all WHO member states (except the US) endorsing the treaty is a big leap forward in the fight against future pandemics.  Crucially it will accelerate appropriate action, for example the commitment we need to enable vaccines to be developed quickly and made globally accessible within the 100 days mission target set by CEPI.

    “This is a global agreement and will only work with global support.  But to make these measures effective, we must also push for investment in regional measures such as the development of ‘pandemic’ manufacturing facilities in Africa in support of diagnostics, vaccines, and other interventions.”

     

    Dr Richard Hatchett, CEO of CEPI, said:

    “Rebecca Solnit once wrote that ‘Perfection is a stick with which to beat the possible.’  Is the Pandemic Agreement perfect?  No.  But no such international agreement can be.

    “Does it represent a huge step forward, in terms of recognising the threat that pandemics pose and as a binding expression of solidarity against this common threat?  Absolutely.  It is now a defining feature of the landscape, under the canopy of which all our efforts going forward will be conducted.

    “Is there a great deal of practical work still to be done to make the world safe from pandemics?  Of course.

    “But this is a moment to celebrate!  And also a moment to rededicate ourselves to the hard work of pandemic prevention, preparedness, and response.”

     

    CEPI statement on the adoption of the Pandemic Agreement: 

    CEPI commends the commitment of countries and negotiators to advancing this once-in-a-generation opportunity to make the world a safer place.  By their nature, pandemics can only be effectively tackled through international cooperation and the adoption of the Pandemic Agreement represents an historic step forward in this regard.  It seeks to drive systemic change that will address the inequity that characterized the response to COVID-19 and brings us closer to realizing the 100 Days Mission goal to respond to future pandemic threats with a new vaccine in just three months.  

    CEPI stands ready to support the implementation of the Pandemic Agreement, including: 

    • Requirements for publicly-funded R&D to include equitable access obligations – such as affordable pricing terms, technology transfer, information sharing;
    • Commitments to support sustainable and geographically distributed production facilities with the capability to scale up for rapid response in a health emergency;
    • The establishment of a multilateral pathogen benefits sharing system that supports rapid and efficient sharing of samples and data on pathogens with pandemic potential to expedite R&D for medical countermeasures.  This, together with a global supply chain and logistics network, will help to strengthen research and innovation and support global access to medical countermeasures based on public health need rather than ability to pay.

    While we celebrate today’s achievement, we must also recognise that the Agreement on its own will not deliver the level of pandemic preparedness the world urgently needs.

    It will take sustained investment, enduring political commitment and unprecedented scientific collaboration to create the systemic change needed to protect not just our own generation, but generations to come.  

     

    Dr Daniela Manno, Clinical Assistant Professor, London School of Hygiene & Tropical Medicine, said:

    “We know pandemics do not respect borders.  COVID-19 demonstrated how quickly infectious diseases can spread and underscored the importance of international cooperation for early detection and response.

    “Adopting this first global agreement on pandemic preparedness and response is a major milestone.  It signals a global commitment to avoiding the fragmented and unequal responses of past crises, and to promoting greater solidarity and equity in future health emergencies.

    “It shows that countries are willing to work together more effectively and more fairly, through timely data sharing, coordinated rapid responses, and fair access to vaccines, diagnostics and treatments.

    “However, while the treaty marks important progress, concerns remain about its strength and enforceability.  For example, the proposal to create a Coordinating Financial Mechanism is a positive step, but it lacks firm commitments to new, long-term funding streams, specifically for low- and middle-income countries.  Without clear financial provisions, LMICs may face increased debt or be forced to divert funding from other essential health services to meet treaty obligations.

    “While the treaty references inclusiveness and community engagement, there needs to be a greater emphasis on integrating local knowledge and enabling community-led decision-making.  This is crucial to avoid top-down approaches that may not reflect the needs and realities of diverse communities, particularly in LMICs.”

     

    Dr Michael Head, Senior Research Fellow in Global Health, University of Southampton, said:

    The WHO Pandemic Agreement is quite a triumph for diplomacy, and will rely hugely on cooperations from the member states.  The draft agreement is full of words such as equity, respect and solidarity.  This is where the WHO is very strong, in providing expert guidance from an ethical and practical standpoint that applies across the world.  However, the Organization does not have much of a role in any legal enforcement.

    “The Agreement makes reference to the International Health Regulations (IHR) 2005.  Member states have a legal obligation to adhere to the IHR, although it’s not fully clear what would happen if a country chooses not to.

    “For example, the USA are technically still a member of WHO, with a one year notice period for withdrawal put forward by the Trump government.  Given their recent commentary on national and global health, one can imagine they may not comply with regulations both currently in place and proposed here under the Agreement.”

    https://apps.who.int/gb/ebwha/pdf_files/WHA78/A78_10-en.pdf

    https://www.who.int/news/item/19-05-2025-member-states-approve-who-pandemic-agreement-in-world-health-assembly-committee–paving-way-for-its-formal-adoption

    https://www.who.int/news/item/20-05-2025-world-health-assembly-adopts-historic-pandemic-agreement-to-make-the-world-more-equitable-and-safer-from-future-pandemics

     

     

    Declared interests

    Prof Sir Andrew Pollard:“Professor Pollard is chair of JCVI which provides independent scientific advice on vaccines to DHSC.  The comment above is given in a personal capacity.”

    Prof Mishal Khan: “No conflicts.”

    Prof Alice Norton: “Professor Alice Norton receives a research grant from the World Health Organization – this does not relate to the Pandemic Agreement.”

    Dr Richard Hatchett: “No conflicts of interest to declare.”

    Dr Michael Head: “No COI from me (and not involved in the Pandemic Treaty in any way).”

    For all other experts, no reply to our request for DOIs was received.

    MIL OSI United Kingdom

  • MIL-OSI USA: Office of the Governor — Travel Release — Gov. Green to Travel To Washington D.C.

    Source: US State of Hawaii

    STATE OF HAWAIʻI 
    KA MOKU ʻĀINA O HAWAIʻI 

    JOSH GREEN, M.D. 
    GOVERNOR
    KE KIAʻĀINA 

    GOVERNOR GREEN TO TRAVEL TO WASHINGTON D.C.

    FOR IMMEDIATE RELEASE
    May 19, 2025

    HONOLULU  ̶  Governor Josh Green, M.D., has been invited by U.S. Senator Richard Blumenthal to testify before the U.S. Permanent Subcommittee on Investigations at a hearing on science and federal health agencies. Governor Green will travel to Washington D.C. on Monday, May 19.

    U.S. Senator Richard Blumenthal of Connecticut is the ranking member of the committee and extended the invitation, to discuss Governor Green’s experience as a physician and public official in addressing outbreaks of infectious diseases, including during the coronavirus pandemic. The U.S. Permanent Subcommittee on Investigations is the chief investigative subcommittee of the U.S. Senate Committee on Homeland Security and Governmental Affairs. Governor Green will return to Hawai‘i on Friday, May 23, 2025.

    Lieutenant Governor Sylvia Luke will serve as acting Governor from the afternoon of May 19 until the afternoon of May 23.

     ###

    Media Contacts:  
    Erika Engle
    Press Secretary
    Office of the Governor, State of Hawai‘i
    Office: 808-586-0120
    Email: [email protected] 

    Makana McClellan
    Director of Communications
    Office of the Governor, State of Hawaiʻi
    Cell: 808-265-0083
    Email: [email protected]

    MIL OSI USA News

  • MIL-OSI United Kingdom: Director disqualified for 11 years after dishonestly securing Covid loan for Lincoln plumbing and heating company

    Source: United Kingdom – Executive Government & Departments

    Press release

    Director disqualified for 11 years after dishonestly securing Covid loan for Lincoln plumbing and heating company

    Carl Barnes, the director of Central Plumbing & Heating Lincoln Ltd, made false statements about the company’s turnover to secure a Bounce Back loan  

    • Carl Barnes applied for a Bounce Back loan of £47,500 for Central Plumbing & Heating Lincoln Ltd.   

    • He declared the company had a turnover of £340,000 when in reality it was nothing.   

    • Barnes has been banned as a company director for 11 years. The Secretary of State accepted a voluntary disqualification undertaking offered by him.   

    The director of a plumbing and heating company has been banned for 11 years after overstating his company’s turnover by hundreds of thousands of pounds to secure a Covid Bounce Back loan.   

    Carl Barnes, of Ollerton Road, Retford, was the director of Central Plumbing & Heating Lincoln Ltd, which was incorporated in April 2016.    

    The company, based on Wavell Drive in Lincoln, made a small profit in its first year of trading, but dormant accounts were filed by Barnes in the following years.   

    In August 2020, the 45-year-old falsely claimed the company had a turnover of £340,000 for 2019, despite the actual turnover being £0. 

    He received a Covid Bounce Back loan for the company of £47,500 which it was not entitled to.   

    Barnes was disqualified as a director for 11 years on 17 April 2025, with the ban beginning on 8 May 2025.   

    Kevin Read, Chief Investigator at the Insolvency Service, said:   

    Carl Barnes exploited the Bounce Back Loan Scheme by providing false information about his company’s turnover.   

    His dishonesty has resulted in this significant director disqualification, which prevents him from forming or managing a company for more than a decade.    

    The Insolvency Service will continue to investigate those who abused this scheme – designed to help small businesses during the pandemic – and bring them to justice.

    Central Plumbing & Heating Lincoln Ltd went into liquidation in October 2022.   

    The disqualification order prevents Barnes from being involved in the promotion, formation or management of a company, without the permission of the court.   

    Further information

    Updates to this page

    Published 20 May 2025

    MIL OSI United Kingdom

  • MIL-OSI New Zealand: BUDGET 2025 – What Vote Health Needs Just to Stay Afloat

    Budget 2025 will need to include $2 billion in additional operational funding this year just for the public health system to stand still.

    “Year on year specialists in our public hospitals are being asked to do more and more,” says ASMS policy director Harriet Wild.

    “If we do not see this level of investment as a minimum it just means the Government is choosing to dig their own hole that much deeper. Again in 12-months’ time they will gamble on the future of our public health system again, knowing they have made the odds that much worse.”

    Two billion dollars is the increase required to meet health cost pressures (which run higher than general inflation) including changes in pricing, volumes, and inflation, as well as the increased need created by a growing and ageing population.

    New Zealand’s population is growing by 1.3% annually.

    New Zealand’s population is also ageing. Almost three-quarters of total life-long healthcare costs occur in the last three years of life. Census data shows 1 in 6 people were aged 65 and older in 2023, this is projected to be 1 in 5 by 2033.

    The need for hospital-based acute care is also increasing. Acute discharges in public hospital increased by 28% between 2014 and 2023. Almost 1.3 million people attended an Emergency Department in 2022/23, a 22.5% increase since 2013/14. Over the same period, the population increased by 16%.

    Two billion dollars will not remedy decades of underfunding of New Zealand’s health system. New Zealand’s total health expenditure (public and private) as a proportion of GDP has remained well below comparable countries for many years. Prior to Covid-19, New Zealand spent 9% of GDP on health, while countries including Australia, Canada, The Netherlands and Sweden spent an average 10.7%.

    The New Zealand Health Survey shows significant volume of unmet health need also remains in our community, with 1.86 million adults experiencing an unmet need for dental care due to cost. 464,000 adults have an unmet need for mental health or addiction services – an increase of 3.3% since 2023.

    While investing in primary care will make people healthier overall, it will also generate more cost for our hospitals as unmet need for secondary care is identified by those primary care providers.

    $1.43 billion was allocated to meet health sector cost pressures (demographic changes, price and wage increases) in the 2023-4 Budget. However, when appearing before health select committee during Scrutiny Week in March 2024, Te Whatu Ora officials acknowledged this fell short of what was required.

    MIL OSI New Zealand News

  • MIL-OSI Security: Westwego Woman Guilty of Conspiracy to Commit Mail Fraud by Defrauding State Offices of Unemployment Insurance

    Source: Office of United States Attorneys

    NEW ORLEANS, LOUISIANA – Acting United States Attorney Michael M. Simpson announced today that REHA JANEE ARVIE,(“ARVIE”), age 34, of Westwego, LA, pled guilty to Conspiracy to Commit Mail Fraud, in violation of Title 18, United States Code, Section 1349. ARVIE faces up to twenty (20) years imprisonment, up to three (3) years of supervised release, a fine up to $250,000.00, or twice the gross gain to the defendant, or twice the gross loss to any victim, and a $100.00 mandatory special assessment fee.

    According to the indictment, beginning in or around July 2020, ARVIE defrauded, and attempted to defraud, various state offices of Unemployment Insurance (“UI”) through the submission of approximately 100 fraudulent UI applications. ARVIE recruited friends and family, via Facebook, to file these fraudulent UI applications. Additionally, ARVIE filed fraudulent UI applications for herself and others, in various states including Arizona, California, Colorado, Hawaii, Indiana, Missouri, Nevada, Pennsylvania, Utah, Texas, and the territory of Guam. ARVIE charged those for whom she filed fraudulent UI claims fees, ranging from    $1,200.00 to $1,500.00. For example, ARVIE obtained $267,612.00 in UI benefits from California’s Employment Development Department. Moreover, during the investigation, ARVIE lied to federal agents during an interview.

    Sentencing in this matter is scheduled for September 10, 2025, before United States District Judge Sarah S. Vance.

    On May 17, 2021, the Attorney General established the COVID-19 Fraud Enforcement Task Force to marshal the resources of the Department of Justice in partnership with agencies across government to enhance efforts to combat and prevent pandemic-related fraud. The Task Force bolsters efforts to investigate and prosecute the most culpable domestic and international criminal actors and assists agencies tasked with administering relief programs to prevent fraud by, among other methods, augmenting and incorporating existing coordination mechanisms, identifying resources and techniques to uncover fraudulent actors and their schemes, and sharing and harnessing information and insights gained from prior enforcement efforts. For more information on the Department’s response to the pandemic, please visit https://www.justice.gov/coronavirus. The Department of Veterans Affairs, Office of the Inspector General, is an active member of the PRAC Fraud Task Force.

    “The PRAC was established to promote transparency and facilitate coordinated oversight of the federal government’s COVID-19 pandemic response. The PRAC’s 20 member Inspectors General identify major risks that cross program and agency boundaries to detect fraud, waste, abuse, and mismanagement in the more than $5 trillion in COVID-19 spending, including spending via the Paycheck Protection Program (PPP), and Economic Injury Disaster Loan (EIDL) program. This case was also supported by the PRAC’s Pandemic Analytics Center of Excellence, which applies the latest advances in analytic and forensic technologies to help OIGs and law enforcement pursue data-driven pandemic relief fraud investigations.”

    Anyone with information about allegations of attempted fraud involving COVID-19 can report it by calling the Department of Justice’s National Center for Disaster Fraud (NCDF) Hotline at 866-720-5721 or via the NCDF Web Complaint Form at https://www.justice.gov/disaster-fraud/ncdf-disaster-complaint-form.

    The United States Attorney’s Office would also like to acknowledge the assistance of the U.S. Department of Labor, Office of Inspector General; the Department of Veterans Affairs, Office of Inspector General; the National Unemployment Insurance Fraud Task Force; The Pandemic Response Accountability Committee; the United States Department of Homeland Security Office of Inspector General COVID Fraud Unit; and the California Employment Development Department with this matter. The prosecution of this case is being handled by Assistant United States Attorney Brian M. Klebba, Chief of the Financial Crimes Unit.

    MIL Security OSI

  • MIL-OSI Russia: Rising to the Challenge: Europe’s Path to Growth and Resilience

    Source: IMF – News in Russian

    May 19, 2025

    Good afternoon,

    Thank you, Karel, for the introduction and CEPS for hosting this event. I would also like to extend a warm thank you to Cinzia and Maarten for taking time out of your busy schedules, and to all of you for joining us today.

    Europe has achieved much over the last 75 years.

    The “economic miracle” of the post-WWII period brought the rapid recovery in income levels. The “Great Moderation” (1980s-2000) following the oil crises in the 1970s offered stable growth at declining inflation rates. And advances in regional integration—for example through the Single European Act in 1986–and global trade helped lift productivity and income levels in Europe. The result was income per capita in advanced European countries growing by two and a half times between 1960 and the end of the century, on par with the US.

    Europe has shown grit when it mattered. Resolute policymaking helped overcome the double blow of the Global Financial Crisis and the European debt crisis. And Europe stepped up again during the Covid-19 pandemic and the energy crisis following Russia’s invasion of Ukraine.

    But more work needs to be done.

    The world is changing fast. Today, we are confronted with a more shock-prone, uncertain, and fragmented world. This adds to a series of domestic challenges in Europe. Some are longstanding: The great European project remains unfinished, the population is aging, climate change requires attention, and there is a worrying productivity gap with the most dynamic economies. Other challenges have become prominent only more recently, such as the need to bolster national and energy security. And, in many countries, there is limited fiscal space to meet these growing challenges.

    Europe must once again step up if it wants to preserve its prosperity. Kicking the can down the road will soon make it impossible to fulfill commitments to social welfare, climate action, and national defense. Delivering on these fronts is existential—Europe’s economic and social model is at stake.

    The deteriorating external environment weighs on Europe’s economic outlook.

    In our latest World Economic Outlook, we project global growth to reach only 2.8 percent this year, in part due to ongoing trade and policy uncertainty. In the United States, growth is expected to slow to 1.8 percent from heightened tariffs, economic uncertainty, and softer demand, while China’s growth forecast is lowered to 4 percent. These numbers do not reflect the latest developments, which could mean lower tariffs than assumed in April. But uncertainty remains extraordinarily high and holds back consumption and investment.

    And trade and policy uncertainty also led us to downgrade growth in Europe despite some offsetting factors: Germany plans to ramp-up infrastructure spending and European defense spending is projected to increase significantly.

    • For the euro area, we expect growth at 0.8 and 1.2 percent in 2025 and 2026, a reduction of 0.2 percentage points in both years since our January projection. Growth in the more trade-exposed CESEE region slows by even more, reaching 2.4 in 2025 and 2.7 in 2026, a downgrade of 0.6 and 0.4 percentage points, respectively.
    • High frequency indicators and euro area GDP flash estimates (excluding volatile figures for Ireland) in the first quarter of the year are consistent with our projections.

    Inflation is decelerating and approaching targets, driven by lower energy prices and tepid demand.

    There are notable risks around the baseline.

    First, an escalation of trade tensions would further weaken external demand and increase uncertainty.

    Second, a reconfiguration of supply chains could impact activity and inflation. In our view, trade diversion to Europe from countries more affected by US tariffs is a small risk on aggregate. But it could lead to losses in export shares for specific sectors in some countries, especially those CESEE countries with persistent real wage growth.

    A third risk is a delay in the necessary fiscal consolidation, which could reignite concerns about repayment capacity.

    So, how can Europe rise to these challenges and secure its prosperity?

    Europe needs an ambitious and concerted push to advance long-stalled reforms to boost growth and economic resilience.

    Action should be carried out both at the EU level to deepen the single market, and domestically to make product and labor markets more growth friendly.

    The forthcoming EU budget for 2028-2034 should support and incentivize the reform push and meet the growing need for European public goods.

    This reform effort must be anchored in a steady macro-policy response and open trade policies.

    Let me look at some of the details.

    Starting with macroeconomic policy…

    …central banks should continue to normalize monetary policy while remaining focused on durably reaching price stability targets. The ECB should lower its policy rate to 2 percent this summer and maintain it there, barring major shocks. In CESEE countries, where inflation is still higher and more persistent, central banks should ease cautiously.

    Fiscal policymakers will have to find ways to accommodate rising spending needs in a sustainable way. In countries where public debt is already high, consolidation is warranted, and reprioritization is necessary to accommodate new spending needs.

    Regarding trade policy, Europe—and indeed everyone—needs more trade.

    The global trade regime has shifted, and some reallocation of resources and reconfiguration of value chains appear inevitable. At the same time, it is important to not over-react.

    For example, while US-China tariffs may divert some trade to Europe, we estimate that even with April’s high tariff rates the aggregate effects would be small—to the order of 0.25 percent of EU GDP or about 3 percent of extra-EU imports. Although the effects could be more pronounced in certain industries, it is far from clear whether safeguard measures are required. Where measures are deployed, they must align with WTO principles, be time-limited, and clearly communicated.

    Europe should avoid tariff escalation; and it should protect people, not stand in the way of structural change.

    Let me now turn to the structural policies Europe needs to boost growth and resilience.

    I will focus on EU and domestic reforms with the highest urgency and potential. I will emphasize their complementarity and the need to pursue comprehensive reform packages to enhance political support.

    I will also highlight the key role that the next EU budget can play in supporting the reform effort, and ultimately secure Europe’s prosperity.

    First, it is high time to reboot the EU single market.

    Europe has come a long way, but the EU single market remains far from complete. For instance, it can take up to 6 months for an EU worker who relocates to another EU country to be legally employed there. Large differences across bankruptcy procedures discourage cross-border investment, while having national stock markets introduces vast inefficiencies in the allocation of capital across the continent. This fragmentation increases costs and hurts business dynamism and growth.

    Full integration of the single market would yield tremendous benefits. Our modeling work shows that a 10 percent reduction in barriers to intra-EU goods trade and multinational production would lift GDP by around 7 percent [4]. But we need to take concrete steps in this direction. In a forthcoming paper [5], we list four priority areas:

    1. Adopting high-quality insolvency rules within a 28th regime for firms to simplify the regulatory landscape
    2. Advancing the capital markets union to boost venture capital and equity investment
    3. Increasing labor mobility across the EU, and
    4. Better integrating the European electricity market

    Presenting these reforms as a package may increase the buy-in from member states that see benefits in some areas more than others, while remaining realistic on feasibility.

    We find that just this package of selected actionable measures could raise EU GDP by approximately 3 percent over the next 10 years—a significant downpayment on the full potential gains from completing the single market.

    Second, advancing EU and domestic policy actions together would magnify the growth impact of reforms.

    In another paper to be published in a few days [6], we also highlight the significant potential gains from domestic reforms.  A package of reform priorities addressing policy gaps in labor markets, business regulation, and credit and capital markets could boost output by approximately 5 percent in advanced European economies and up to 7 percent in CESEE countries over the medium term.

    A coordinated reform effort at both domestic and EU levels would likely yield benefits that exceed the cumulative returns from isolated actions in the two areas. For example, advancing the capital markets union would boost the effect of domestic initiatives to support innovative startups. And improving skill levels at the national level will amplify EU R&D efforts.

    Across all areas, think smart and big. Structuring reforms as “packages” in which everyone can see direct benefits can enhance domestic political support and facilitate successful implementation.

    Third, the EU budget has the potential to be a powerful lever for advancing policy priorities across both the European Union and its member states.

    The EU’s Multiannual Financial Framework (MFF) has helped tackle shared challenges—promoting economic convergence through cohesion policy and strengthening resilience via NextGenerationEU. To meet existing and emerging challenges, we suggest that the 2028–2034 MFF be revamped along three key lines [7].

    1. Prioritize European public goods. The EU budget should allocate more resources to key areas of shared strategic interest—such as R&D, the clean energy transition, energy security, and defense. These are domains where collective investment delivers greater efficiency and cost savings compared to national-level efforts. To meet these needs, expenditure targeted at European public goods would need to increase from 0.4 percent of GNI to 0.9 percent.
    2. Maximize the budget impact. With over 50 programs, the current EU budget is fragmented, limiting its effectiveness. Consolidating programs around core EU priorities and shifting toward a performance-based budgeting model would enhance efficiency, improve coordination among member states, and better align national reforms with EU-level objectives.
    3. Strengthen financing through enhanced own resources and borrowing capacity. Establishing borrowing as a regular financing tool—backed by robust own resources for repayment—would enable more strategic, long-term investment while spreading the financial burden more evenly across time and member states.

    Fourth, a more integrated Europe is also a more resilient Europe.

    The spike and volatility in energy prices following Russia’s invasion of Ukraine, along with last month’s blackouts in Spain and Portugal, underscore the urgency of a coordinated European energy policy and establishing an integrated energy infrastructure.

    On the financial side, advancing the capital markets union would not only channel savings into productive investment, but also facilitate portfolio diversification and significantly improve risk sharing.

    Fiscal policy—particularly the EU budget—has an important role to play in supporting energy integration and risk sharing.

    Let me conclude by stressing that Europe stands at a critical junction.

    The world is changing, and Europe must once again demonstrate its ability to step up and deliver. Strengthening –and, yes, even upholding—prosperity requires a decisive and concerted reform push at both domestic and EU levels that enhances growth and resilience while maintaining openness to the world.

    It is time to act now. It is time to act together.

    References

    [1] Eble, Stephanie, Alexander Pitt, Irina Bunda, Oyun Erdene Adilbish, Nina Budina, Gee Hee Hong, Moheb T Malak, Sabiha Mohona, Alla Myrvoda, and Keyra Primus. 2025. “Long-Term Spending Pressures in Europe,” IMF Departmental Papers 2025/002.

    [2] Scott R. Baker, Nicholas Bloom, Steven J. Davis. 2016. “Measuring Economic Policy Uncertainty,” The Quarterly Journal of Economics, Volume 131, Issue 4, Pages 1593–1636.

    [3] Boehm, Christoph E., Andrei A. Levchenko, and Nitya Pandalai-Nayar. 2023. “The Long and Short (Run) of Trade Elasticities,” American Economic Review 113 (4): 861–905.

    [4] Baba, Chikako, Ting Lan, Aiko Mineshima, Florian Misch, Magali Pinat, Asghar Shahmoradi, Jiaxiong Yao, and Rachel van Elkan. 2023. “Geoeconomic Fragmentation: What’s at Stake for the EU,” IMF Working Paper 2023/245, International Monetary Fund, Washington, DC.

    [5] Arnold, Nathaniel, Allan Dizioli, Alexandra Fotiou, Jan Frie, Burcu Hacibedel, Tara Iyer, Huidan Lin, Malhar Nabar, Hui Tong, and Frederik Toscani. Forthcoming. “Lifting Binding Constraints on Growth in Europe. Actionable Priorities to Deepen the Single Market,” IMF Working Paper.

    [6] Budina, Nina, Oyun Adilbish, Diego Cerdeiro, Romain Duval, Balázs Égert, Dmitriy Kovtun, Anh Thi Ngoc Nguyen, Augustus Panton, and Catalina Michelle Tejada. Forthcoming. “Europe’s National-Level Structural Reform Priorities,” IMF Working Paper.

    [7] Busse, Matthias, Huidan Lin, Malhar Nabar, and Jiae Yoo. Forthcoming. “Making the EU’s Multiannual Financial Framework Fit for Purpose,” IMF Working Paper.

    [8] Darvas, Zsolt, and Conor McCaffrey. 2024. “Management of debt liabilities in the EU budget under the post-2027 MFF,” November 2024.

    [9] Draghi, Mario. 2024. “The future of European competitiveness,” September 2024.

    [10] Cimadomo, Jacopo, Massimo Giuliodori, Andras Lengyel, Haroon Mumtaz. 2023. “Changing patterns of risk-sharing channels in the United States and the euro area,” ECB Working Paper No 2849.

    IMF Communications Department
    MEDIA RELATIONS

    PRESS OFFICER:

    Phone: +1 202 623-7100Email: MEDIA@IMF.org

    https://www.imf.org/en/News/Articles/2025/05/19/sp051925-ak-rising-to-the-challenge-europe-path-to-growth-and-resilience

    MIL OSI

    MIL OSI Russia News

  • MIL-OSI Global: Covid-19 death tolls in Europe highlight stark regional differences in 2020 and 2021

    Source: The Conversation – France – By Florian Bonnet, Démographe et économiste, spécialiste des inégalités territoriales, Ined (Institut national d’études démographiques)

    The political decisions made during 2020 and 2021 to combat the Covid-19 pandemic profoundly altered daily life. Professionally, societies faced partial unemployment and widespread adoption of remote work; personally, individuals endured lockdowns and social distancing measures. These interventions aimed to reduce infection rates and ease pressure on healthcare systems, with the primary public health goal of minimizing deaths.


    A weekly e-mail in English featuring expertise from scholars and researchers. It provides an introduction to the diversity of research coming out of the continent and considers some of the key issues facing European countries. Get the newsletter!

    More than five years after the pandemic began, what do we know about its impact on human longevity? Here’s a closer look.

    A decline in global life expectancy

    Initial assessments of the pandemic’s toll have been refined over time. According to a World Health Organization (WHO) report published in May 2024, global life expectancy declined by 1.8 years between 2019 and 2021, erasing a decade of progress. These estimates rely on “excess mortality”, a metric that measures the difference between observed mortality during the pandemic and expected mortality in its absence.

    Excess mortality can be quantified using different indicators, such as the number of excess deaths. However, comparing this indicator between countries of different sizes and age structures can be challenging. Another informative metric is the loss of life expectancy at birth, calculated globally by organisations such as the WHO.

    The regular calculation, publication and dissemination of excess mortality indicators are vital for comparing the pandemic’s impact across countries at the national level. However, it is important to recognise that the pandemic did not affect all areas within countries equally. Variability in the severity of the pandemic’s impact often stemmed from differing confinement strategies implemented to contain the virus.

    This uneven distribution highlights the need to quantify these indicators at a more granular geographical level. Such localised analysis can reveal the regions most severely affected, providing valuable insights into the pandemic’s effects and enabling the development of targeted response strategies.

    In a series of studies conducted in 2024, we introduced an innovative method to calculate excess mortality at the regional level. We used this method to estimate excess mortality in 561 European regions in 2020 and expanded the scope to 569 regions across 25 countries in 2020 and 2021. The findings, based on loss of life expectancy at birth, reveal stark contrasts in the pandemic’s impact across Europe.

    In 2020, significant declines in life expectancy were observed in northern Italy and Spain

    Figure 1 illustrates the spatial distribution of estimated losses of life expectancy in 2020. These losses were highest in northern Italy and central Spain. In the Italian regions of Bergamo and Cremona, life expectancy dropped by nearly four years, while Piacenza experienced a decline of three and a half years. In Spain, the regions of Segovia, Ciudad Real, Cuenca and Madrid saw losses of approximately three years.

    The losses were even more pronounced among men (data not presented here), who were disproportionately affected by the pandemic. In Cremona, the decline in life expectancy among men reached nearly five years, while in Bergamo, it was close to four and a half years.

    Figure 1: Estimated loss of observed life expectancy at birth (e0) in 2020 across 569 regions in 25 European countries. Estimates are for both sexes combined.
    Fourni par l’auteur

    Eastern Europe, particularly Poland, along with eastern Sweden and northern and eastern France, also experienced significant, though less severe, declines. In France, the Paris region and areas near the German border recorded the highest losses, ranging from 1.5 to 2 years.

    In contrast, other regions saw much smaller impacts. This is particularly true for southern Italy, much of Scandinavia and Germany, southern parts of the United Kingdom, and western France. In these regions, observed life expectancy is close to what would have been expected in the absence of the pandemic. In France, the implementation of lockdown measures in March and November likely prevented the pandemic from spreading across the entire country from the initial clusters in the north and east.

    In 2021, a shift in the pandemic toward Eastern Europe

    Figure 2 shows the estimated losses of life expectancy in 2021. At a glance, the regions most affected by excess mortality during the Covid-19 pandemic differed significantly from those in 2020. The most substantial losses were concentrated in Eastern Europe.

    Figure 2: Estimated loss of observed life expectancy at birth (e0) in 2021 across 569 regions in 25 European countries. Estimates are for both sexes combined.
    Fourni par l’auteur

    Among regions where life expectancy declined by more than two years, 61 of Poland’s 73 regions, 12 of the Czech Republic’s 14 regions, all eight Hungarian regions, and seven of Slovakia’s eight regions were affected. In contrast, only one Italian region and one Spanish region experienced losses exceeding two years, despite these countries being heavily impacted in 2020.

    Germany saw much greater losses in 2021 than in 2020, particularly in its eastern regions, where declines often exceeded 1.5 years. In southern Saxony, Halle and Lusatia, losses approached two years. Conversely, Spain and Scandinavia recorded the lowest declines in life expectancy.

    In France, the losses were more uniform than in 2020, generally ranging from 0 to 1.5 years. The highest loss occurred in the Parisian suburbs, particularly Seine-Saint-Denis, where life expectancy fell by 1.5 years – or two years for men.

    What is the overall assessment for these two years?

    To determine the overall impact of 2020 and 2021 in terms of life expectancy loss, we used an indicator that sums up the years of life lost due to the pandemic over this two-year period. This method allows us to rank the 569 European regions.

    The regions most affected were Pulawy, Bytom and Przemyski in southeastern Poland, along with Kosice and Presov in eastern Slovakia. Among the top 50 regions, Eastern Europe dominated, with 36 Polish regions, six Slovakian regions, two Czech regions, one Hungarian region, and both Lithuanian regions included. Italian regions such as Cremona, Bergamo and Piacenza also ranked high, falling between the 15th and 30th positions. In France, Seine-Saint-Denis ranked 81st, while all other French regions were outside the top 100.

    It is crucial to analyse the impact of a crisis like the Covid-19 pandemic at a fine geographical scale, as within-country disparities can be significant. This was particularly evident in Italy in 2020, where the north was far more affected than the south, and in Germany in 2021, with stark differences between the west and the east.

    Our study highlighted the severe impact of the pandemic in specific European regions, where life expectancy losses exceeded three years. The most affected regions shifted over time, moving from areas with traditionally high life expectancy (such as northern Italy, central Spain and the greater Paris region) in 2020 to regions with traditionally lower life expectancy (Eastern Europe) in 2021. France was relatively spared compared to the rest of Europe, with the notable exception of Seine-Saint-Denis.

    The coming years will be critical in determining whether life expectancy levels can return to their long-term trajectories or if the pandemic has caused lasting structural changes in certain regions.

    Les auteurs ne travaillent pas, ne conseillent pas, ne possèdent pas de parts, ne reçoivent pas de fonds d’une organisation qui pourrait tirer profit de cet article, et n’ont déclaré aucune autre affiliation que leur organisme de recherche.

    ref. Covid-19 death tolls in Europe highlight stark regional differences in 2020 and 2021 – https://theconversation.com/covid-19-death-tolls-in-europe-highlight-stark-regional-differences-in-2020-and-2021-246374

    MIL OSI – Global Reports

  • MIL-OSI United Kingdom: Recruitment consultant sentenced after fraudulently using Covid loans for personal purposes

    Source: United Kingdom – Executive Government & Departments

    Press release

    Recruitment consultant sentenced after fraudulently using Covid loans for personal purposes

    Suspended sentence for Bounce Back Loan fraudster

    • Rico Iheagwara fraudulently applied for two £20,000 Bounce Back Loans during the summer of 2020  

    • Iheagwara’s SJR Recruitment Limited company was not trading at the time of the applications 

    • SJR Recruitment was placed into liquidation in 2021 with liabilities of more than £67,000

    A recruitment consultant who fraudulently spent Covid support funds for personal purposes has been handed a suspended sentence. 

    Rico Iheagwara secured two Bounce Back Loans worth £20,000 each from different banks for his Essex-based SJR Recruitment Limited company when businesses were only entitled to a single loan under the scheme. 

    Iheagwara, 36, of River Meads, Stanstead Abbotts, Hertfordshire, was sentenced to 18 months in prison, suspended for 18 months, for fraud when he appeared at St Albans Crown Court on Friday 16 May. 

    He was also ordered to complete 120 hours of unpaid work and 15 days of rehabilitation activity. 

    David Snasdell, Chief Investigator at the Insolvency Service, said: 

    Rico Iheagwara blatantly abused a taxpayer-backed scheme designed to support genuine small businesses through the pandemic. He knew he was not entitled to support yet continued with his fraudulent applications nonetheless. 

    Iheagwara’s business was not trading at the time of his application so he was not entitled to a single penny from the scheme, let alone the £40,000 he fraudulently secured. 

    Tackling Covid support scheme abuse remains a key priority for the Insolvency Service and we will not hesitate to prosecute fraudsters such as Iheagwara who stole from the public purse during a national emergency.

    SJR Recruitment was incorporated in January 2017 with Iheagwara as its sole director. The company’s registered office address was on High Road in Loughton. 

    Iheagwara was also the sole signatory on both company bank accounts which were opened in May 2020, just one month before his first fraudulent application. 

    For both applications, made in June and July 2020, Iheagwara claimed the company’s turnover was £82,000. 

    Iheagwara transferred the first £20,000 loan into his personal account on the same day he received the funds. For the second loan, he moved all £20,000 into his personal account the following day. 

    None of the £40,000 was used for the economic benefit of his business. Insolvency Service analysis of bank statements suggested that the funds were used for everyday expenses and paid to various family members. 

    In interviews, Iheagwara said he spent the funds on rent, paying off personal finance and supporting his children. 

    SJR Recruitment went into liquidation in April 2021. No repayments were made on the loans. 

    The Insolvency Service is seeking to recover the fraudulently obtained funds under the Proceeds of Crime Act 2002.

    Further information

    Updates to this page

    Published 19 May 2025

    MIL OSI United Kingdom

  • MIL-OSI United Kingdom: Cutting edge sustainable tech: the Servita supplier story 

    Source: United Kingdom – Executive Government & Departments

    Case study

    Cutting edge sustainable tech: the Servita supplier story 

    Servita specialises in helping organisations transform so they can thrive at the forefront of science and technology. 

    When Servita set up in the UK in 2016, it had a team of around 30. Now it’s 180 and counting. 

    Servita specialises in helping organisations transform through technology so they can overcome entrenched ways of working and operations. 

    UK managing director Rich Story said: “Keeping ourselves and our customers at the forefront of science and technology, whilst remembering it is people that remain at the centre of transformation, is our modus operandi.”

    Servita’s key capabilities including user-centred design, where the company has strong links to the Government Digital Service, and expertise in advanced, highly secure, high performance and sustainable cloud-hosted solutions. Sustainable cloud and carbon net zero are part of Servita’s core technical architecture principles.  

    Artificial intelligence, machine learning and natural language processing are also strong competencies and people in the team have published research papers with Harvard University on natural language and semantic programming. 

    Servita has been active in the Vivace community since 2020. 

    Explaining what attracted the company to the Accelerated Capability Environment (ACE), Story said: “A community of suppliers that gets access to novel problems at the heart of government, facilitated by an organisation that seeks to create an environment to innovate whilst keeping a firm eye on time, cost and outcomes – it really chimed with us.”

    One early major project was working as part of the ACE core team on the UK government’s Covid response, helping drive an innovation agenda as part of strategic objectives. Story said: “Despite the backdrop it was one of the best things I’ve been part of during my career.”

    For a health commission, Servita delivered a digital tool capable of measuring and reporting digital deficit, so an organisation could understand where it stands digitally in relation to industry standards, and how much it would cost to get to where it needs to be. 

    Servita also remains an integral part of ACE’s wider NHS work, where it built and currently maintains a national data information exchange that links all of the secondary care landscape in England to the NHS App. 

    Story said: “We love the efficiency in tendering and speed to impact for delivery. ACE looks to deliver outcomes in 12-15 weeks which is good for government and the taxpayer. 

    “Most of all we love the types of projects ACE give us access to. As a business it’s led to us having some of our best case references and it’s critical for us to be able to give our staff access to projects that really make a difference as it gives us an identity and sense of pride.”

    He added: “Our mission statement is to keep ourselves and our partners at the cutting edge of science and technology with a focus on sustainable solutions for good and delivery excellence. 

    “I can honestly say that ACE and Vivace have enabled us to stay true to this by virtue of the novel and important problem spaces that they give us access to. ACE has introduced us to new customers and also to other like-minded suppliers that we have forged valuable relationships with. 

    “These things have all been significant in shaping our business.”

    Updates to this page

    Published 19 May 2025

    MIL OSI United Kingdom

  • MIL-OSI: CBAK Energy Reports First Quater 2025 Unaudited Financial Results

    Source: GlobeNewswire (MIL-OSI)

    DALIAN, China, May 19, 2025 (GLOBE NEWSWIRE) — CBAK Energy Technology, Inc. (NASDAQ: CBAT) (“CBAK Energy,” or the “Company”) a leading lithium-ion battery manufacturer and electric energy solution provider in China, today reported its unaudited financial results for the first quarter ended March 31, 2025.

    First Quater of 2025 Financial Results

    Net revenues1 were $34.9 million, representing a decrease of 41% compared to $58.8 million in the same period of 2024. The substantial decline primarily stems from our Dalian facilities, where a major portion of customers are in the residential energy supply sector. These facilities are currently undergoing a product portfolio upgrade, transitioning from Model 26650 to Model 40135. Customers who previously purchased Model 26650 are now in a transitional phase of testing and validating the new Model 40135. We anticipate a gradual recovery as both existing and potential customers complete the validation of Model 40135.

    Among these revenues, detailed revenues from our battery business are:

    Battery Business   2024
    First Quater
        2025
    First Quater
        % Change
    YoY
    Net Revenues ($)   44,837,869     20,363,338     -54.6
    Gross Profits ($)   18,458,522     4,720,102     -74.4
    Gross Margin   41.2 %   23.2 %  
    Net Income ($)   11,682,429     336,861     -97.1
    Net Revenues from Battery Business on Applications ($)                
    Electric Vehicles   480,181     537,507     11.9
    Light Electric Vehicles   1,510,292     2,844,874     88.4
    Residential Energy Supply & Uninterruptable supplies   42,847,396     16,980,957     -60.4
    Total   44,837,869     20,363,338     -54.6
    1 Net revenues consist of the Company’s self-operated battery business and Hitrans, which was acquired in 2021, an independently managed raw materials business.


    Cost of revenues
    was $30.14 million, representing a decrease of 24.7% from $40.0 million in the same period of 2024.

    Gross profit was $4.8 million, representing an decrease of 74.43% from $18.78 million in the same period of 2024. Gross margin was 13.7%, compared to 31.9% in the same period of 2024.

    Operating loss amounted to $2.86 million, compared to an operating income of $10.3 million in the same period of 2024.

    Net loss attributable to shareholders of CBAK Energy was $1.58 million, compared to net income attributable to shareholders of CBAK Energy of $9.8 million in the same period of 2024.

    Basic and diluted loss per share were both $0.02, compared to basic and diluted income per share of $0.11 in 2024.

    Zhiguang Hu, Chief Executive Officer of the Company, commented, “As anticipated, we experienced a significant 41% year-over-year decline in net revenues. This decrease was expected, as Model 26650 — a cell developed in 2006 and still produced at our Dalian facilities — has become largely outdated. Both existing and potential customers are currently transitioning from Model 26650 to the more advanced Model 40135. We are confident that, upon completing the construction of new manufacturing lines for Model 40135 in the second half of this year, and as customers finalize product validation, our revenues will begin to recover gradually.”

    Jiewei Li, Chief Financial Officer and Secretary of the Board, added, “As Mr. Hu emphasized, we expect to recover once the product portfolio upgrade at our Dalian facilities is completed. Meanwhile, our Nanjing facilities continue to experience strong growth momentum, driven by robust market demand for Model 32140, our most advanced and flagship product to date. Additionally, we are in the final stages of securing a long-term order from one of our key customers, which we hope to finalize and share with our shareholders in the near future.”

    Conference Call

    CBAK Energy’s management will host an earnings conference call at 9:00 AM U.S. Eastern Time on Monday, May 19, 2025 (9:00 PM Beijing/Hong Kong Time on May 19, 2025).

    For participants who wish to join our call online, please visit:
    https://edge.media-server.com/mmc/p/wfu5unoh

    Participants who plan to ask questions during the call will need to register at least 15 minutes prior to the scheduled call start time using the link provided below. Upon registration, participants will receive the conference call access information, including dial-in numbers, a unique pin, and an email with detailed instructions.

    Participant Online Registration:
    https://register-conf.media-server.com/register/BIb49b754e574a43e68068965ba0234966

    Once completing the registration, please dial-in at least 10 minutes before the scheduled start time of the conference call and enter the personal pin as instructed to connect to the call.

    A replay of the conference call may be accessed within seven days after the conclusion of the live call at the following website: https://edge.media-server.com/mmc/p/wfu5unoh

    The earnings release and the link for the replay are available at ir.cbak.com.cn

    About CBAK Energy

    CBAK Energy Technology, Inc. (NASDAQ: CBAT) is a leading high-tech enterprise in China engaged in the development, manufacturing, and sales of new energy high power lithium and sodium batteries, as well as the production of raw materials for use in manufacturing high power lithium batteries. The applications of the Company’s products and solutions include electric vehicles, light electric vehicles, energy storage and other high-power applications. In January 2006, CBAK Energy became the first lithium battery manufacturer in China listed on the Nasdaq Stock Market. CBAK Energy has multiple operating subsidiaries in Dalian, Nanjing, Shaoxing and Shangqiu, as well as a large-scale R&D and production base in Dalian.

    For more information, please visit ir.cbak.com.cn

    Safe Harbor Statement

    This press release contains “forward-looking statements” that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, strategy and plans, and our expectations for future operations, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. We have attempted to identify forward-looking statements by terminology including “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “should,” or “will” or the negative of these terms or other comparable terminology. Our actual results may differ materially or perhaps significantly from those discussed herein, or implied by, these forward-looking statements.

    Any forward-looking statements contained in this press release are only estimates or predictions of future events based on information currently available to our management and management’s current beliefs about the potential outcome of future events. Whether these future events will occur as management anticipates, whether we will achieve our business objectives, and whether our revenues, operating results, or financial condition will improve in future periods are subject to numerous risks. There are a significant number of factors that could cause actual results to differ materially from statements made in this press release, including: significant legal and operational risks associated with having substantially all of our business operations in China, that the Chinese government may exercise significant oversight and discretion over the conduct of our business and may intervene in or influence our operations at any time, which could result in a material change in our operations and/or the value of our securities or could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and could cause the value of such securities to significantly decline or be worthless, the effects of the global Covid-19 pandemic or other health epidemics, changes in domestic and foreign laws, regulations and taxes, the volatility of the securities markets; and other risks including, but not limited to, the ability of the Company to meet its contractual obligations, the uncertain markets for the Company’s products and business, macroeconomic, technological, regulatory, or other factors affecting the profitability of our products and solutions that we discussed or referred to in the Company’s disclosure documents filed with the U.S. Securities and Exchange Commission (the “SEC”) available on the SEC’s website at www.sec.gov, including the Company’s most recent Annual Report on Form 10-K as well as in our other reports filed or furnished from time to time with the SEC. You should read these factors and the other cautionary statements made in this press release. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.

    For further inquiries, please contact:

    In China:

    CBAK Energy Technology, Inc.
    Investor Relations Department
    Email: ir@cbak.com.cn

    CBAK Energy Technology, Inc. and Subsidiaries
    Condensed Consolidated Balance Sheets
    As of December 31, 2024 and March 31, 2025
    (Unaudited)
    (In US$ except for number of shares)
     
      December 31,
    2024
        March 31,
    2025
     
    Assets          
    Current assets          
    Cash and cash equivalents $ 6,724,360     $ 4,052,010  
    Pledged deposits   54,061,642       43,482,693  
    Term deposits   4,237,090       5,530,030  
    Trade and bills receivable, net   32,938,918       40,835,093  
    Inventories   22,851,027       30,803,486  
    Prepayments and other receivables   20,004,966       17,991,265  
    Receivables from former subsidiary   12,399       9,011  
    Income tax recoverable   566,458       455,342  
    Total current assets   141,396,860       143,158,930  
                   
    Property, plant and equipment, net   85,486,829       84,283,683  
    Construction in progress   42,526,859       51,527,443  
    Long-term investments, net   2,246,494       2,313,725  
    Prepaid land use rights   11,075,973       11,056,715  
    Intangible assets, net   382,962       268,398  
    Deposit paid for acquisition of long-term investments   15,864,318       15,949,095  
    Operating lease right-of-use assets, net   3,237,849       2,906,652  
    Total assets $ 302,218,144     $ 311,464,641  
                   
    Liabilities              
    Current liabilities              
    Trade and bills payable   84,724,386       93,398,948  
    Short-term bank borrowings   26,087,350       29,301,628  
    Other short-term loans   335,715       335,905  
    Accrued expenses and other payables   58,285,635       50,305,373  
    Payable to a former subsidiary, net   419,849       418,211  
    Deferred government grants, current   556,214       559,186  
    Product warranty provisions   23,426       23,000  
    Operating lease liability, current   1,268,405       1,159,373  
    Total current liabilities   171,700,980       175,501,624  
                   
    Long-term bank borrowings         4,131,890  
    Deferred government grants, non-current   7,580,255       10,272,610  
    Product warranty provisions   420,688       417,565  
    Operating lease liability, non-current   2,449,056       2,397,859  
    Total liabilities   182,150,979       192,721,548  
                   
    Commitments and contingencies              
                   
    Shareholders’ equity              
    Common stock $0.001 par value; 500,000,000 authorized; 90,083,396 issued and 89,939,190 outstanding as of December 31, 2024; and 90,083,868 issued and 89,939,662 outstanding as of March 31, 2025   90,083       90,083  
    Donated shares   14,101,689       14,101,689  
    Additional paid-in capital   247,842,445       247,869,511  
    Statutory reserves   1,230,511       3,042,602  
    Accumulated deficit   (122,605,730 )     (125,997,055 )
    Accumulated other comprehensive loss   (14,919,345 )     (14,248,434 )
        125,739,653       124,858,396  
                   
    Less: Treasury shares   (4,066,610 )     (4,066,610 )
                   
    Total shareholders’ equity   121,673,043       120,791,786  
    Non-controlling interests   (1,605,878 )     (2,048,693 )
    Total equity   120,067,165       118,743,093  
                   
    Total liabilities and shareholder’s equity $ 302,218,144     $ 311,464,641  

     

    CBAK Energy Technology, Inc. and Subsidiaries
    Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
    For the three months ended March 31, 2024 and 2025
    (Unaudited)
    (In US$ except for number of shares)
     
      Three months ended
    March 31,
     
      2024     2025  
    Net revenues $ 58,822,432     $ 34,938,901  
    Cost of revenues   (40,041,385 )     (30,137,167 )
    Gross profit   18,781,047       4,801,734  
    Operating expenses:              
    Research and development expenses   (2,815,518 )     (3,023,961 )
    Sales and marketing expenses   (1,724,032 )     (896,050 )
    General and administrative expenses   (4,092,527 )     (3,804,137 )
    Allowance of credit losses and bad debts written off, net   114,013       58,395  
    Total operating expenses   (8,518,064 )     (7,665,753 )
    Operating income (loss)   10,262,983       (2,864,019 )
    Finance income, net   9,663       45,120  
    Other income, net   367,438       712,792  
    Share of (loss) income of equity investee   (18,824 )     55,125  
    Income (loss) before income tax   10,621,260       (2, 050,982 )
    Income tax expenses   (1,048,786 )      
    Net income (loss)   9,572,474       (2, 050,982 )
    Less: Net loss attributable to non-controlling interests   263,976       471,748  
    Net income (loss) attributable to shareholders of CBAK Energy Technology, Inc. $ 9,836,450     $ (1,579,234 )
                   
    Net income (loss)   9,572,474       (2,050,982 )
    Other comprehensive income (loss)              
    – Foreign currency translation adjustment   (1,906,048 )     699,844  
    Comprehensive income (loss)   7,666,426       (1,315,138 )
    Less: Comprehensive loss attributable to non-controlling interests   274,223       442,816  
    Comprehensive income (loss) attributable to CBAK Energy Technology, Inc. $ 7,940,649     $ (908,322 )
                   
    Income (loss) per share              
    – Basic $ 0.11     $ (0.02 )
    – Diluted $ 0.11     $ (0.02 )
                   
    Weighted average number of shares of common stock:              
    – Basic   89,925,024       89,938,690  
    – Diluted   90,123,965       89,938,690  

    The MIL Network

  • MIL-OSI New Zealand: Legal News – Former NZ Associate Minister Of Foreign Affairs Calls On NZ Government To Uphold International Law Over US Designation of Cuba

    Source: Hon Matthew Robson

    Former NZ Associate Minister Of Foreign Affairs, Hon Matt Robson, has called on the New Zealand Government to uphold International Law.

    “New Zealand prides itself on being in the forefront of countries supporting the international rule of law and not the international rule of might ”, said former Associate Foreign Minister in the Helen Clark government, the Hon Matt Robson.

    “To uphold this principled position Foreign Minister, the Hon Winston Peters, must strongly condemn the US action of placing Cuba on its “List of Non-Cooperative Terrorism countries.

    “This illegal act is a further breach of international law alongside the ever-tightening unilateral sanctions on Cuba, in place since 1960, which have been condemned as illegal by an overwhelming vote in the UN General Assembly, including that of New Zealand vote” said the Hon Matt Robson.

    “Cuba is recognised by the UN for its commitment to anti-terrorism measures. The irony is that it has been the United States that has supported terrorism against Cuba from the attempted assassination of its leaders, military invasions ,economic sabotage to the bombing of a Cuban airliner and protection in the US of the culprits.”

    “Cuba is renowned not for terrorism but for sending medical professionals to the poorest countries of the world since 1960, training doctors in Cuba from those countries, including many from Pacific nations, and during Covid providing specialist health personnel, including to developed Italy , to world acclaim”.

    “The Hon Winston Peters should place New Zealand on the side of the vast majority of countries supporting international law and condemn the United States for its illegal persecution of a developing country,” Hon Matt Robson said.

    MIL OSI New Zealand News

  • MIL-OSI Global: Why we fall for fake health information – and how it spreads faster than facts

    Source: The Conversation – USA – By Angshuman K. Kashyap, PhD candidate in Health Communication, University of Maryland

    Should you share that health-related Instagram post? Catherine McQueen/Moment via Getty Images

    In today’s digital world, people routinely turn to the internet for health or medical information. In addition to actively searching online, they often come across health-related information on social media or receive it through emails or messages from family or friends.

    It can be tempting to share such messages with loved ones – often with the best of intentions.

    As a global health communication scholar studying the effects of media on health and development, I explore artistic and creative ways to make health information more engaging and accessible, empowering people to make informed decisions.

    Although there is a fire hose of health-related content online, not all of it is factual. In fact, much of it is inaccurate or misleading, raising a serious health communication problem: Fake health information – whether shared unknowingly and innocently, or deliberately to mislead or cause harm – can be far more captivating than accurate information.

    This makes it difficult for people to know which sources to trust and which content is worthy of sharing.

    The allure of fake health information

    Fake health information can take many forms. For example, it may be misleading content that distorts facts to frame an issue or individual in a certain context. Or it may be based on false connections, where headlines, visuals or captions don’t align with the content. Despite this variation, such content often shares a few common characteristics that make it seem believable and more shareable than facts.

    For one thing, fake health information often appears to be true because it mixes a grain of truth with misleading claims.

    For example, early in the COVID-19 pandemic, false rumors suggested that drinking ethanol or bleach could protect people from the virus. While ethanol or bleach can indeed kill viruses on surfaces such as countertops, it is extremely dangerous when it comes into contact with skin or gets inside the body.

    Stopping to check the facts helps stem the spread of misinformation.
    World Health Organization adaptation from Siouxsie Wiles and Toby Morris in The Spinoff, CC BY-SA

    Another marker of fake health information is that it presents ideas that are simply too good to be true. There is something appealingly counterintuitive in certain types of fake health information that can make people feel they have access to valuable or exclusive knowledge that others may not know. For example, a claim such as “chocolate helps you lose weight” can be especially appealing because it offers a sense of permission to indulge and taps into a simple, feel-good solution to a complex problem. Such information often spreads faster because it sounds both surprising and hopeful, validating what some people want to believe.

    Sensationalism also drives the spread of fake health information. For instance, when critics falsely claimed that Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases and the chief medical adviser to the president at the time, was responsible for the COVID-19 pandemic, it generated a lot of public attention.

    In a study on vaccine hesitancy published in 2020, my colleagues and I found that controversial headlines in news reports that go viral before national vaccination campaigns can discourage parents from getting their children vaccinated. These headlines seem to reveal sensational and secret information that can falsely boost the message’s credibility.

    The pull to share

    The internet has created fertile ground for spreading fake health information. Professional-looking websites and social media posts with misleading headlines can lure people into clicking or quickly sharing, which drives more and more readers to the falsehood. People tend to share information they believe is relevant to them or their social circles.

    In 2019, an article with the false headline “Ginger is 10,000x more effective at killing cancer than chemo” was shared more than 800,000 times on Facebook. The article contained several factors that make people feel an urgency to react and share without checking the facts: compelling visuals, emotional stories, misleading graphs, quotes from experts with omitted context and outdated content that is recirculated.

    Visual cues like the logos of reputable organizations or photos of people wearing white medical coats add credibility to these posts. This kind of content is highly shareable, often reaching far more people than scientifically accurate studies that may lack eye-catching headlines or visuals, easy-to-understand words or dramatic storylines.

    But sharing content without verifying it first has real-world consequences. For example, studies have found that COVID-19-related fake information reduces people’s trust in the government and in health care systems, making people less likely to use or seek out health services.

    Unfounded claims about vaccine side effects have led to reduced vaccination rates globally, fueling the return of dangerous diseases, including measles.

    Check it out before you share.

    Social media misinformation, such as false claims about cinnamon being a treatment for cancer, has caused hospitalizations and even deaths. The spread of health misinformation has reduced cooperation with important prevention and treatment recommendations, prompting a growing need for medical professionals to receive proper training and develop skills to effectively debunk fake health information.

    How to combat the spread of fake health information

    In today’s era of information overload in which anyone can create and share content, being able to distinguish between credible and misleading health information before sharing is more important than ever. Researchers and public health organizations have outlined several strategies to help people make better-informed decisions.

    Whether health care consumers come across health information on social media, in an email or through a messaging app, here are three reliable ways to verify its accuracy and credibility before sharing:

    • Use a search engine to cross-check health claims. Never rely on a single source. Instead, enter the health claim into a reputable search engine like Google and see what trusted sources have to say. Prioritize information from established organizations like the World Health Organization, Centers for Disease Control and Prevention, United Nations Children’s Fund or peer-reviewed journals like The Lancet or Journal of the American Medical Association. If multiple reputable sources agree, the information is more likely to be reliable. Reliable fact-checking websites such as FactCheck.org and Snopes can also help root out fake information.

    • Evaluate the source’s credibility. A quick way to assess a website’s trustworthiness is to check its “About Us” page. This section usually explains who is behind the content, their mission and their credentials. Also, search the name of the author. Do they have recognized expertise or affiliations with credible institutions? Reliable websites often have domains ending in .gov or .edu, indicating government or educational institutions. Finally, check the publication date. Information on the internet keeps circulating for years and may not be the most accurate or relevant in the present context.

    • If you’re still unsure, don’t share. If you’re still uncertain about the accuracy of a claim, it’s better to keep it to yourself. Forwarding unverified information can unintentionally contribute to the spread of misinformation and potentially cause harm, especially when it comes to health.

    Questioning dubious claims and sharing only verified information not only protects against unsafe behaviors and panic, but it also helps curb the spread of fake health information. At a time when misinformation can spread faster than a virus, taking a moment to pause and fact-check can make a big difference.

    Angshuman K. Kashyap does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

    ref. Why we fall for fake health information – and how it spreads faster than facts – https://theconversation.com/why-we-fall-for-fake-health-information-and-how-it-spreads-faster-than-facts-250718

    MIL OSI – Global Reports

  • MIL-OSI Security: California Woman Sentenced to Federal Prison for Stealing Nearly $2 Million in Two Separate Fraud Schemes

    Source: Office of United States Attorneys

    PORTLAND, Ore.—A California woman was sentenced to federal prison today for stealing nearly $1.3 million in Covid-relief program funds and failing to pay the IRS more than $700,000 in payroll taxes she collected from the employees of a small business in Salem, Oregon.

    Jamie McGowen, 43, was sentenced to 37 months in federal prison and five years’ supervised release. She was also ordered to pay $2,072,860 in restitution to the IRS and U.S. Small Business Administration (SBA).

    According to court documents, McGowen was the owner or partial owner of nine separate companies including Salem Outsourcing, Inc., a payroll processing company based in Salem. Between August 2016 and December 2019, McGowen provided payroll processing services to a small business also located in Salem. During this time, she failed to pay the IRS $705,613 in payroll taxes she withheld from the paychecks of the company’s employees. Instead, McGowen kept the money for herself and used a portion of the funds to, among other things, purchase a 100% ownership stake in the same company whose payroll taxes she had stolen.

    In a separate scheme, between April 2020 and December 2021, McGowen stole more than $1.2 million from federal relief programs intended to help small businesses during the Covid-19 pandemic, including the Paycheck Protection Program, Economic Injury Disaster Loan program, and Restaurant Revitalization Fund. McGowen made numerous false statements in 15 separate loan applications, including by stating she did not own any other company, inflating the number of employees and revenues, and providing false tax documents. McGowen also falsely claimed on loan forgiveness applications that her companies had used the funds received for payroll. In reality, McGowen transferred the money around her businesses, to her father, and to her personal checking account, and paid off personal credit cards.

    On October 12, 2022, a federal grand jury in Portland returned a seven-count indictment charging McGowen with wire fraud, bank fraud, and money laundering. On December 11, 2024, she pleaded guilty to one count each of wire fraud and bank fraud, and two counts of money laundering.

    This case was investigated by the SBA Office of Inspector General (SBA-OIG) and IRS Criminal Investigation (IRS-CI). It was prosecuted by Meredith Bateman, Assistant U.S. Attorney for the District of Oregon.
     

    MIL Security OSI

  • MIL-OSI Security: South Florida Tax Preparer, Two Others Charged with Conspiring to Defraud Covid-19 Relief Program

    Source: United States Department of Justice (National Center for Disaster Fraud)

    MIAMI –The last of three defendants made his initial appearance in Miami federal court yesterday to face an indictment charging the men with conspiracy to commit wire fraud while scheming to fraudulently obtain Paycheck Protection Program (PPP) loans.

    PPP loans were intended to provide economic relief to small businesses during the Covid-19 pandemic. According to the allegations in the indictment, between May 2020 and March 2021, Guillermo Lopez Carrazana, Christian Mendoza, and Max Alberto Mera Ulloa, all residents of Miami-Dade County, conspired to submit over 165 false and fraudulent PPP loan applications to the U.S. Small Business Administration (SBA), which administered the emergency relief program under the CARES Act. The PPP was designed to help businesses maintain payroll and cover essential expenses during the pandemic. It is alleged that the defendants received $6.5 million in COVID relief money through the fraud.  

    It is alleged that Carrazana, Mendoza (a tax preparer) and Ulloa owned and operated various businesses, including G LUX LLC, Global Tax & Accounting Group Corp, CM Logistics Systems LLC and Max Mera Corporation. Along with others, the defendants allegedly submitted fraudulent loan applications that misrepresented payroll and employee information to obtain large sums of money under false pretenses.

    The indictment further alleges that the defendants engaged in a kickback scheme, offering and receiving payments in exchange for referring additional individuals to participate in the fraudulent loan applications. It is also alleged that the defendants and the other fraudsters did not use the proceeds of the PPP loans for their intended purpose, instead they used the funds to enrich themselves.

    U.S. Attorney Hayden P. O’Byrne for the Southern District of Florida, Special Agent in Charge Brett D. Skiles of the FBI, Miami Field Office, and Special Agent in Charge Emmanuel Gomez of the IRS Criminal Investigation (IRS-CI), Miami Field Office made the announcement.

    FBI Miami and IRS-CI, Miami Field Office are investigating the case. Assistant U.S. Attorney Roger Cruz is prosecuting the case.

    An indictment is merely an allegation. All defendants are presumed innocent unless and until proven guilty beyond a reasonable doubt in a court of law.

    Related court documents and information may be found on the website of the District Court for the Southern District of Florida at www.flsd.uscourts.gov or at http://pacer.flsd.uscourts.gov under case number 25-cr-20178.

    ###

    MIL Security OSI

  • MIL-OSI Asia-Pac: DH urges high-risk individuals to receive COVID-19 vaccines as soon as possible as COVID-19 activity hits one-year high in Hong Kong

    Source: Hong Kong Government special administrative region

    DH urges high-risk individuals to receive COVID-19 vaccines as soon as possible as COVID-19 activity hits one-year high in Hong Kong 
    “After the resumption of normalcy, Hong Kong experienced cycles of active periods of COVID-19 in every six to nine months. Taking into account local and global epidemiological data in recent years, the CHP is of the view that COVID-19 has evolved into an endemic disease with a periodic pattern. According to the CHP’s analysis, the active periods are associated with the changes in the predominant circulating strains and declining herd immunity in Hong Kong. In early 2024, the predominant strains circulated locally changed from XBB to JN.1; while in the third quarter of 2024, they changed from JN.1 to KP.2 and KP.3; and they have further changed to XDV since late March this year. There is no evidence suggesting that XDV will cause more severe disease. Nevertheless, the changing nature of the virus should not be taken lightly. The CHP will continue to closely monitor the situation of the variant strains in accordance with the World Health Organization’s recommendation, and be cautious of the possible emergence of more virulent or vaccine-mismatched strains of the virus in the future,” the Controller of the CHP, Dr Edwin Tsui, said.
     
    According to the latest surveillance data as of the week ending May 10, the viral load of the SARS-CoV-2 virus from sewage surveillance, the test positivity rate and the cases tested positive by nucleic acid tests in the laboratory have continued to rise over the past four weeks. In particular, the percentage of respiratory samples testing positive for the SARS-CoV-2 virus gradually increased to 13.66 per cent from 6.21 per cent four weeks ago (the week of April 6 to 12), which is a record high in the past year. For sewage surveillance, the per capita viral load of SARS-CoV-2 virus was around 710 000 copy/litre, which was also significantly higher than that of about 390 000 copy/litre four weeks ago. During the same period, the consultation rate of COVID-19 cases at Accident and Emergency departments, general out-patient clinics and sentinel private medical practitioner clinics also recorded a significant increase.
     
    “According to the surveillance data after the resumption of normalcy, there were two relatively active periods of COVID-19 in Hong Kong, which lasted for about 15 weeks from April to July 2023 and for about seven weeks from February to March last year. COVID-19 became more active in mid-April of this year (i.e. about four weeks ago). Based on previous statistics, we expect the activity level of COVID-19 to remain at a higher level for at least the next few weeks,” said Dr Tsui.
     
    Regarding severe and fatal cases, in the past four weeks, the CHP recorded a total of 81 COVID-19 severe cases (including 30 fatal cases) involving adults. Epidemiological investigation showed that 83 per cent of the patients being elderly persons aged 65 or above, and more than 90 per cent of these elderly cases had underlying illnesses. Only one case had received a booster dose of COVID-19 vaccine in the past six months.
     
    For children, the CHP has recorded five severe cases (no fatal case) so far this year. Of which, two have underlying illnesses and three cases have not received the initial dose of the COVID-19 vaccine. “This shows that even children who have been in good health can experience severe complications from COVID-19 infection. Therefore, I hope that parents will not hesitate to bring their children to complete the initial dose of the COVID-19 vaccine as soon as possible. The currently prevalent XDV strain is a related variant of JN.1. Therefore, the JN.1 vaccine used in Hong Kong is effective in preventing the disease, reducing the risk of severe illness and death, and enhancing herd immunity,” said Dr Tsui.
     
    “Currently, the proportion of high-risk groups, especially the elderly, receiving booster doses of the vaccine is relatively low. This suggests that the public does not attach much importance to vaccination. Based on the surveillance data and vaccination figures, the CHP projected that about 75 per cent of the elderly aged 65 or above living in Residential Care Homes for the Elderly and 90 per cent of those living in the community had not received booster dose of the COVID-19 vaccine timely according to the CHP’s recommendation. I would like to reiterate my appeal to the high-risk groups, especially the elderly and persons with underlying illnesses, to receive an additional booster dose of the COVID-19 vaccine as soon as possible,” Dr Tsui added.
     
    Apart from vaccination, the public should maintain stringent personal, environmental and hand hygiene at all times to minimise the risk of infecting COVID-19 and other respiratory infectious diseases. High-risk persons (e.g. persons with underlying medical conditions or persons who are immunocompromised) should wear surgical masks when visiting public places. The general public should also wear a surgical mask when travelling on public transport or staying in crowded places. When respiratory symptoms appear, one should wear a surgical mask, consider avoiding going to work or school, avoid going to crowded places and seek medical advice promptly.
    ???
    For the latest surveillance data, members of the public can refer to the CHP’s weekly COVID-19 & Flu ExpressIssued at HKT 20:36

    NNNN

    MIL OSI Asia Pacific News